Document:

NEITHER THIS WARRANT NOR THE UNDERLYING
SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. 

 

 

WARRANT TO PURCHASE COMMON STOCK

 

OF

 

Manhattan Pharmaceuticals, Inc.

 

	Warrant No. W-	
        _____, 201_

         

THIS CERTIFIES THAT,
for value received, [Name of Holder], having an address at [_______________________] (the “Investor”), is entitled
to subscribe for and purchase at the Exercise Price (defined below) from Manhattan Pharmaceuticals, Inc., a Delaware corporation,
(the “Company”) at any time during the period commencing on the Initial Exercise Date (as herein defined) and
ending at 5:00 p.m., Eastern time, on _____, 201_ (the “Expiration Date”), [________] shares of the Common
Stock (as herein defined), in accordance with the terms thereof (as such number may be adjusted as provided herein, the “Warrant
Shares”), subject to the provisions and upon the terms and conditions hereinafter set forth in this Warrant (“Warrant”).
This Warrant is being issued pursuant to the terms of the Subscription Agreement, dated as of _____, 201_, as amended, by and among
the Company, the original Investor and the other parties named therein (the “Purchase Agreement”).

 

1.Definitions. As used in this
Warrant, the following terms have the meanings set forth below:

 

“Aggregate
Number” shall mean, at any time to be determined, the number of Warrant Shares for which this Warrant may be exercised
at such time.

 

“Business
Day” shall mean any day other than a Saturday, Sunday or other day on which commercial banks in New York, New York are
authorized or required by law or executive order to close.

 

“Common Stock”
shall mean the common stock, par value $.001 per share, of the Company (and any other securities into which or for which the Common
Stock may be converted or exchanged pursuant to a dividend, stock split, plan of recapitalization, reorganization, merger, sale
of assets or otherwise) into which this Warrant will be exercisable.

 

“Company”
shall have the meaning set forth in the introductory paragraph hereto.

    	1

    	 

    

“Exercise
Price” shall mean $0.04 per share of Common Stock, subject to adjustment pursuant to Section 6 below.

 

“Expiration
Date” shall have the meaning set forth in the introductory paragraph hereto.

 

“Fair Market
Value” shall mean, with respect to a share of Common Stock on any date: (i) the fair market value of the outstanding
Common Stock over the ten (10) trading days immediately prior to the date of calculation based upon the closing price per
share of Common Stock on each such day, as officially reported on the principal national securities exchange on which the Common
Stock is then listed or admitted to trading; or (ii) if subsection (i) is not applicable, a market price per share determined
in good faith by the Board of Directors of the Company, which shall be deemed to be “Fair Market Value.”

 

“Holder”
shall mean the Investor or any holder of an interest in the Warrant or the outstanding Warrant Shares who becomes a holder in compliance
with Section 4 hereof.

 

“Initial Exercise
Date” shall mean _____, 201_.

 

“Investor”
shall have the meaning set forth in the introductory paragraph hereto.

 

“Person”
shall mean any individual, corporation, partnership, firm, limited liability company, joint venture, trust, association, unincorporated
organization, university, group, joint-stock company or other entity.

 

“Securities
Act” shall mean the Securities Act of 1933, as amended, or any similar federal statute, and the rules and regulations
promulgated thereunder as the same shall be in effect at the time.

 

“Stock Combination”
shall have the meaning set forth in Section 6(a)(i).

 

“Stock Dividend”
shall have the meaning set forth in Section 6(a)(i).

 

“Stock Subdivision”
shall have the meaning set forth in Section 6(a)(i).

 

“Transaction”
shall have the meaning set forth in Section 6(b).

 

“Warrant Register”
shall have the meaning set forth in Section 8.

 

“Warrant Shares”
shall have the meaning set forth in the preamble.

 

2.Exercise of Warrant.

 

(a)Beginning on the Initial Exercise
Date, the rights represented by this Warrant may be exercised by the Holder hereof, in whole or in part (but not as to a fractional
share of Common Stock), by (A) the delivery of this Warrant, together with a properly completed Notice of Exercise in the
form attached hereto, to the principal office of the Company at 787 Seventh Avenue, 48th Floor, New York, New York 10019
(or to such other address as the Company may designate by notice in writing to the Holder) and (B) payment to the Company
of the Exercise Price for the Warrant Shares being purchased by cash or by certified check or bank draft. The Company agrees that
the shares so purchased shall be deemed to be issued to the Holder as the record owner of such shares as of the close of business
on the date on which this Warrant shall have been delivered to the Company and payment made for such shares as aforesaid. Certificates
for the shares so purchased shall be delivered to the Holder within ten (10) Business Days after the rights represented by
this Warrant shall have been so exercised, and, unless this Warrant has expired, a new Warrant representing, and with an Aggregate
Number equal to, the number of Warrant Shares, if any, with respect to which this Warrant shall not then have been exercised, in
all other respects identical with this Warrant, shall also be issued and delivered to the Holder within such time, or, at the request
of such Holder, appropriate notation may be made on this Warrant and signed by the Company and the same returned to such Holder.
The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery
of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing
the right to purchase the remaining number of Warrant Shares. The Company shall, upon request of the Holder, use its reasonable
best efforts to deliver Warrant Shares hereunder electronically through The Depository Trust Company or another established clearing
corporation performing similar functions.

 

    	2

    	 

    

(b)Transfer Restriction Legend.
Each certificate for Warrant Shares issued upon exercise of this Warrant, unless at the time of exercise the offer and sale of
such Warrant Shares are registered under the Securities Act, shall bear the following legend (and any additional legend required
by applicable law or rule) on the face thereof:

 

THE OFFER AND SALE OF THE SHARES OF
STOCK REPRESENTED HEREBY HAVE NOT BEEN REGISTERED PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAW.
NEITHER THESE SHARES, NOR ANY PORTION THEREOF OR INTEREST THEREIN, MAY BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS THE
SAME ARE REGISTERED AND QUALIFIED IN ACCORDANCE WITH SAID ACT AND ANY APPLICABLE STATE SECURITIES LAW, OR, IN THE OPINION OF COUNSEL
REASONABLY SATISFACTORY TO THE COMPANY, SUCH REGISTRATION AND QUALIFICATION ARE NOT REQUIRED.

 

The provisions of Section 4
shall be binding upon all holders of certificates for Warrant Shares bearing the above legend and shall also be applicable to all
holders of this Warrant. The legend endorsed on the certificates for Warrant Shares shall be removed and the Company shall issue
a certificate without such legend to the holder thereof at such time as the securities evidenced thereby cease to be restricted
securities upon the earliest to occur of (i) a registration statement with respect to the resale of such securities shall have
become effective under the Securities Act and such securities shall have been disposed of in accordance with such registration
statement, or (ii) the securities shall have been resold to the public pursuant to Rule 144 (or any successor provision) under
the Securities Act.

 

    	3

    	 

    

(c)Expenses and Taxes on Exercise.
The Company shall pay all expenses, taxes and other charges payable in connection with the preparation, execution and delivery
of any stock certificates and substitute Warrants pursuant to this Section 2, except that, in case such stock certificates
or Warrants shall be registered in a name or names other than the name of the Holder of this Warrant, funds sufficient to pay all
stock transfer taxes which shall be payable upon the execution and delivery of such stock certificates or Warrants shall be paid
by the Holder to the Company at the time the Company delivers such stock certificates or Warrants to the Company for exercise.
The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant
or receiving Warrant Shares upon exercise hereof.

 

(d)Company Obligations. The
Company’s obligations to issue and deliver Warrant Shares in accordance with the terms hereof are absolute and unconditional,
irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof,
the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation
or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation
or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance which might otherwise
limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Nothing herein shall limit
a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company’s failure to deliver certificates representing
shares of Common Stock upon exercise of this Warrant as required pursuant to the terms hereof.

 

3.Redemption.

 

Each Warrant shall be
redeemable at the option of the Company at a redemption price equal to $0.001 per share of Common Stock purchasable under such
Warrant at any time after the Common Stock of the Company is traded on an Over-the-Counter Bulletin Board or on a national securities
exchange and the per share average closing price of the Common Stock equals or exceeds an amount that is twice the Exercise Price
under such Warrant for a period of 30 consecutive trading days; provided that Warrants may not be redeemed by the Company unless
the resale of the shares of Common Stock purchasable under the Warrants has been registered under the Securities Act or such shares
of Common Stock are otherwise freely tradable.

 

4.Warrants and Warrant Shares Not
Registered; Transferee Restrictions.

 

(a)Each Holder, by acceptance thereof,
represents and acknowledges that the offer and sale of this Warrant and the Warrant Shares which may be purchased upon exercise
of this Warrant are not being registered under the Securities Act, that the issuance of this Warrant and the offering and sale
of such Warrant Shares are being made in reliance on the exemption from registration under Section 4(2) of the Securities
Act as not involving any public offering and that the Company’s reliance on such exemption is predicated in part on the representations
made by the initial Holder of this Warrant to the Company that such Holder (i) is acquiring this Warrant for investment purposes
for its own account, with no present intention of reselling or otherwise distributing the same in violation of the Securities Act,
subject, nevertheless, to any requirement of law that the disposition of its property shall at all times be within its control,
(ii) is an “accredited investor” as defined in Regulation D under the Securities Act, and (iii) has
such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the investments
made or to be made in connection with the acquisition and exercise of this Warrant. Neither this Warrant nor the related Warrant
Shares may be transferred except pursuant to an effective registration statement under the Securities Act or upon the conditions
specified in Section 4(b).

 

    	4

    	 

    

(b)Notice of Transfer, Opinion of
Counsel. Each Holder, by acceptance hereof, agrees that prior to the disposition of this Warrant or of any Warrant Shares,
other than pursuant to an effective registration under the Securities Act, such Holder will give written notice to the Company
expressing such Holder’s intention to effect such disposition and describing briefly such Holder’s intention as to
the manner in which this Warrant or the Warrant Shares theretofore issued or thereafter issuable upon exercise hereof, are to be
disposed together with an opinion of counsel as may be designated by such Holder and reasonably satisfactory to the Company as
to the necessity or non-necessity of registration under the Securities Act. If in the opinion of such counsel, the proposed disposition
does not require registration under the Securities Act of the disposition of this Warrant and/or the Warrant Shares issuable or
issued upon the exercise of this Warrant, such Holder shall be entitled to dispose of this Warrant and/or the Warrant Shares theretofore
issued upon the exercise hereof, all in accordance with the terms of the notice delivered by such Holder to the Company. The Company
is entitled to rely on the most recent written notice from the Holder with respect to the ownership of the Warrant.

 

5.Representations, Warranties and
Covenants of the Company.

 

(a)The Company hereby represents and
warrants that (i) it has full corporate power and authority to execute and deliver this Warrant, (ii) the execution and delivery
of this Warrant and the consummation by the Company of the transactions contemplated hereby have been duly and validly approved
by all necessary corporate action on the part of the Company and (iii) this Warrant has been duly executed and delivered by the
Company and constitutes the legal, valid and binding obligation of the Company, enforceable in accordance with its terms.

 

(b)The Company covenants and agrees
that (i) during the period within which the rights represented by this Warrant may be exercised, the Company will have at all times
authorized, and reserved for the purpose of issue or transfer upon exercise of the rights evidenced by this Warrant, a sufficient
number of shares of Common Stock to provide therefore, (ii) the Warrant Shares issued pursuant to the exercise of this Warrant
will, upon issuance, be duly and validly issued, fully paid and non-assessable and (iii) the Company shall use its commercially
reasonable efforts to procure at its sole expense the listing of all Warrant Shares then registered for public sale (subject to
issuance or notice of issuance) on all stock exchanges on which the shares of Common Stock are then listed.

 

6.Adjustments of Aggregate Number.

 

(a)Adjustments. The Aggregate
Number, after taking into consideration any prior adjustments pursuant to this Section 6, shall be subject to adjustment
from time to time as follows and, thereafter, as adjusted, shall be deemed to be the Aggregate Number hereunder. No adjustments
shall be made under this Section 6 as a result of the issuance by the Company of the Warrant Shares upon exercise of
this Warrant.

 

    	5

    	 

    

(i)Stock Dividends;
Subdivisions and Combinations. In case at any time or from time to time the Company shall:

 

(A)issue to the holders
of the Common Stock a dividend payable in, or other distribution of, Common Stock (a “Stock Dividend”),

 

(B)subdivide its
outstanding shares of Common Stock into a larger number of shares of Common Stock, including, without limitation, by means of a
stock split (a “Stock Subdivision”), or

 

(C)combine its outstanding
shares of Common Stock into a smaller number of shares of Common Stock (a “Stock Combination”),

 

then the Aggregate Number in effect immediately
prior thereto shall be (1) proportionately increased in the case of a Stock Dividend or a Stock Subdivision and (2) proportionately
decreased in the case of a Stock Combination. In the event the Company shall declare or pay, without consideration, any dividend
on the Common Stock payable in any right to acquire Common Stock for no consideration, then the Company shall be deemed to have
made a Stock Dividend in an amount of shares equal to the maximum number of shares issuable upon exercise of such rights to acquire
Common Stock.

 

(ii)Miscellaneous.
The following provisions shall be applicable to the making of adjustments of the Aggregate Number provided above in this Section 6(a):

 

(A)Whenever the Aggregate
Number is adjusted pursuant to this Section 6(a), the Exercise Price per Warrant Share payable upon exercise of this
Warrant shall be adjusted by multiplying the Exercise Price immediately prior to such adjustment by a fraction, the numerator of
which shall be the Aggregate Number prior to such adjustment, and the denominator of which shall be the Aggregate Number following
such adjustment.

 

(B)If the Company
shall take a record of the holders of the Common Stock for the purpose of entitling them to receive a dividend or distribution
or subscription or purchase rights and shall, thereafter and before the distribution to stockholders thereof, legally abandon its
plan to pay or deliver such dividend, distribution, subscription or purchase rights, then no adjustment shall be required by reason
of the taking of such record and any such adjustment previously made in respect thereof shall be rescinded and annulled.

 

(b)Changes in Common Stock.
In case at any time the Company shall initiate any transaction or be a party to any transaction (including, without limitation,
a merger, consolidation, share exchange, sale, lease or other disposition of all or substantially all of the Company’s assets,
liquidation, recapitalization or reclassification of the Common Stock or other transaction) in connection with which the previous
outstanding Common Stock shall be changed into or exchanged for different securities of the Company or securities of another corporation
or interests in a non-corporate entity or other property (including cash) or any combination of the foregoing (each such transaction
being herein called a “Transaction”), then, as a condition of the consummation of the Transaction and without
duplication of any adjustment made pursuant to Section 6(a)(i), lawful, enforceable and adequate provision shall be
made so that the Holder shall be entitled to receive upon exercise of this Warrant at any time on or after the consummation of
the Transaction, in lieu of the Warrant Shares issuable upon such exercise prior to such consummation, the securities or other
property (including cash) to which such Holder would have been entitled upon consummation of the Transaction if such Holder had
exercised this Warrant immediately prior thereto (subject to adjustments from and after the consummation date as nearly equivalent
as possible to the adjustments provided for in this Section 6). The foregoing provisions of this Section 6(b)
shall similarly apply to successive Transactions. If holders of Common Stock are given any choice as to the securities, cash or
property to be received in a Transaction, then the Holder shall be given the same choice as to the consideration it receives upon
any exercise of this Warrant following such Transaction. At the Holder’s request, any successor to the Company or surviving
entity in such Transaction shall issue to the Holder a new warrant consistent with the foregoing provisions.

 

    	6

    	 

    

(c)Public Financing Adjustment.
Notwithstanding the adjustments in Section 6(a)(i), if the Common Stock of Company is not traded on an Over-the-Counter Bulletin
Board or a national securities exchange on or before the first anniversary of the Initial Exercise Date, then the Warrant Shares
will be adjusted by multiplying the Warrant Shares immediately prior to the first anniversary by two (2). For adjustments made
to the number of Warrant Shares pursuant to this Section 6(c), the Exercise Price immediately prior to such adjustment will remain
unchanged.

 

(d)Notices.

 

(i)Notice of Proposed
Actions. In case the Company shall propose (A) to pay any Stock Dividend payable in stock of any class to the holders
of the Common Stock or to make any other distribution to the holders of the Common Stock, (B) to effect any reclassification
of the Common Stock, (C) to effect any recapitalization, Stock Subdivision, Stock Combination or other capital reorganization,
(D) to effect any consolidation or merger, share exchange, or sale, lease or other disposition of all or substantially all
of its property, assets or business, (E) to effect a Transaction, or any other liquidation, dissolution or winding up of the
Company, or (F) to effect any other action which would require an adjustment under this Section 6, then in each
such case the Company shall give to the Holder written notice of such proposed action, which shall specify the date on which a
record is to be taken for the purposes of such Stock Dividend, Stock Subdivision, Stock Combination, or distribution, or the date
on which such Transaction, reclassification, recapitalization, reorganization, consolidation, merger, share exchange, sale, lease,
transfer, disposition, liquidation, dissolution, winding up or other transaction is to take place and the date of participation
therein by the holders of Common Stock, if any such date is to be fixed, or the date on which the transfer of Common Stock is to
occur, and shall also set forth such facts with respect thereto as shall be reasonably necessary to indicate the effect of such
action on the Common Stock and on the Aggregate Number after giving effect to any adjustment which will be required as a result
of such action. Such notice shall be so given in the case of any action covered by clause (A) or (B) above at least ten (10)
days prior to the record date for determining holders of the Common Stock for purposes of such action and, in the case of any other
such action, at least ten (10) days prior to the earlier of the date of the taking of such proposed action or the date of participation
therein by the holders of Common Stock.

 

    	7

    	 

    

(ii)Adjustment
Notice. Whenever the Aggregate Number is to be adjusted pursuant to this Section 6, unless otherwise agreed by
the Holder, the Company shall promptly (and in any event within twenty (20) Business Days after the event requiring the adjustment)
prepare a certificate signed by the principal executive officer or the principal financial officer of the Company, setting forth,
in reasonable detail, the event requiring the adjustment and the method by which such adjustment is to be calculated. The Company
shall keep at its principal office copies of all such certificates and cause the same to be available for inspection at said office
during normal business hours by the Holder or any prospective purchaser of the Warrant (in whole or in part) if so designated by
the Holder.

 

7.Exchange, Replacement and Assignability.
This Warrant is exchangeable, upon the surrender hereof by the Holder at the office or agency of the Company described in Section 2,
for new Warrants of like tenor and date representing in the aggregate the right to purchase the number of Warrant Shares which
may be purchased hereunder, each of such new Warrants to represent the right to purchase such number of Warrant Shares as shall
be designated by such Holder at the time of such surrender. Upon receipt of evidence satisfactory to the Company of the loss, theft,
destruction or mutilation of Warrants and, in the case of any such loss, theft or destruction, of an indemnity letter (reasonably
satisfactory to the Company) of an institutional holder of such Warrants, or in other cases, of a bond of indemnity or other security
satisfactory to the Company, or, in the case of any such mutilation, upon surrender or cancellation of Warrants, the Company will
issue to the Holder a new Warrant of like tenor and date, in lieu of this Warrant or such new Warrants, representing the right
to purchase the number of Warrant Shares which may be purchased hereunder. Subject to compliance with Section 4, this
Warrant and all rights hereunder are transferable in whole or in part upon the books of the Company by the registered Holder hereof
in person or by duly authorized attorney, and new Warrants shall be made and delivered by the Company, of the same tenor and date
as this Warrant but registered in the name of the transferees, upon surrender of this Warrant, duly endorsed, to the appropriate
office or agency of the Company. All expenses, taxes (other than stock transfer taxes) and other charges payable in connection
with the preparation, execution and delivery of Warrants pursuant to this Section 7 shall be paid by the Company.

 

8.Registration of Warrant. The
Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”),
in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of record of this
Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.

 

9.Warrant Agent. The Company
shall serve as warrant agent under this Warrant. Upon 30 days’ notice to the Holder, the Company may appoint a new warrant
agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation
to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent
transfers substantially all of its corporate trust or stockholder services business shall be a successor warrant agent under this
Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent
to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s last address as shown on the Warrant Register.

 

    	8

    	 

    

10.Transfer Books, No Rights as
Shareholder, Survival of Rights. The Company will at no time close its transfer books against the transfer of this Warrant
or any Warrant Shares in any manner which interferes with the timely exercise of this Warrant. This Warrant shall not entitle the
Holder to any voting rights or any rights as a shareholder of the Company. The rights and obligations of the Company, of the Holder
of this Warrant and of any Holder of Warrant Shares issued upon exercise of this Warrant pursuant to the terms of this Warrant
shall survive the exercise of this Warrant.

 

11.No Inconsistent Agreements.
The Company shall not hereafter enter into any agreement with respect to its securities which is inconsistent with or violates
the rights granted to the Holders in this Warrant.

 

12.Amendment and Waiver.

 

(a)It is agreed that any waiver, permit,
consent or approval of any kind or character on the Holder’s part of any breach or default under this Warrant, or any waiver
on the Holder’s part of any provisions or conditions of this Warrant must be in writing.

 

(b)Any amendment, supplement or modification
of or to any provision of this Warrant, any waiver of any provision of this Warrant and any consent to any departure by any party
from the terms of any provision of this Warrant shall be effective only if it is made or given in writing and signed by the Company
and the Holder.

 

(c)Any amendment or waiver consented
to as provided in this Section 12 is binding upon each future Holder of this Warrant and upon the Company without regard
to whether this Warrant has been marked to indicate such amendment or waiver.

 

13.Rights of Transferees. Subject
to compliance with Section 4, the rights granted to the Holder hereunder of this Warrant shall pass to and inure to
the benefit of all subsequent transferees of all or any portion of the Warrant (provided that the Holder and any transferee shall
hold such rights in proportion to their respective ownership of the Warrant and Warrant Shares) until extinguished pursuant to
the terms hereof.

 

14.Headings. The headings in
this Warrant are for convenience of reference only and shall not constitute a part of this Warrant, nor shall they affect their
meaning, construction or effect.

 

15.Notices. All notices, demands
and other communications provided for or permitted hereunder shall be in writing and shall be deemed to have been given: (a) when
delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized
overnight courier (receipt requested); (c) on the date sent by facsimile or e-mail of a PDF document (with confirmation of transmission)
if sent during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the
recipient; or (d) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid.
Such communications must be sent to the respective parties at the addresses indicated below (or at such other address for a party
as shall be specified in a notice given in accordance with this Section 15).  

 

    	9

    	 

    

 

	If to the Company:	
        Manhattan Pharmaceuticals, Inc.

        787 Seventh Avenue, 48th Floor

        New York, NY 10019

        Attn: Chief Executive Officer

         

         

	with a copy to:	
        Alston & Bird LLP

        90 Park Avenue

        New York, NY 10016

        Attn: Mark McElreath, Esq.

         

	If to the Holder:	
        ____________________

        ____________________

        ____________________

        ____________________

        

         

	 	 

16.Successors and Assigns. This
Warrant shall be binding upon and inure to the benefit of the parties hereto and their respective successors or heirs and personal
representatives and permitted assigns; provided, that the Company shall have no right to assign its rights, or to delegate
its obligations, hereunder without the prior written consent of the Holder.

 

17.Governing
Law. This Agreement and (unless otherwise provided) all amendments hereof and waivers and consents hereunder shall be governed
by the laws of the State of New York, notwithstanding any conflict of law provision to the contrary. THE
COMPANY HEREBY CONSENTS AND AGREES THAT THE STATE OR FEDERAL COURTS LOCATED IN NEW YORK COUNTY, CITY OF NEW YORK, NEW YORK, SHALL
HAVE EXCLUSIVE JURISDICTION TO HEAR AND DETERMINE ANY CLAIMS OR DISPUTES BETWEEN THE COMPANY AND THE HOLDER PERTAINING TO THIS
WARRANT OR ANY OF THE OTHER TRANSACTION DOCUMENTS OR TO ANY MATTER ARISING OUT OF OR RELATING TO THIS WARRANT OR ANY OF THE OTHER
TRANSACTION DOCUMENTS, PROVIDED, THAT THE HOLDER AND THE COMPANY ACKNOWLEDGE THAT ANY APPEALS FROM THOSE COURTS MAY HAVE TO BE
HEARD BY A COURT LOCATED OUTSIDE OF NEW YORK COUNTY, AND, PROVIDED, FURTHER, NOTHING IN THIS WARRANT SHALL BE DEEMED OR OPERATE
TO PRECLUDE THE HOLDER FROM BRINGING SUIT OR TAKING OTHER LEGAL ACTION IN ANY OTHER JURISDICTION TO REALIZE ON THE COLLATERAL OR
ANY OTHER SECURITY FOR THE OBLIGATIONS, OR TO ENFORCE A JUDGMENT OR OTHER COURT ORDER IN FAVOR OF THE HOLDER. THE COMPANY EXPRESSLY
SUBMITS AND CONSENTS IN ADVANCE TO SUCH JURISDICTION IN ANY ACTION OR SUIT COMMENCED IN ANY SUCH COURT, AND THE COMPANY HEREBY
WAIVES ANY OBJECTION WHICH IT MAY HAVE BASED UPON LACK OF PERSONAL JURISDICTION, IMPROPER VENUE OR FORUM NON CONVENIENS AND HEREBY
CONSENTS TO THE GRANTING OF SUCH LEGAL OR EQUITABLE RELIEF AS IS DEEMED APPROPRIATE BY SUCH COURT. THE COMPANY HEREBY WAIVES PERSONAL
SERVICE OF THE SUMMONS, COMPLAINT AND OTHER PROCESS ISSUED IN ANY SUCH ACTION OR SUIT AND AGREES THAT SERVICE OF SUCH SUMMONS,
COMPLAINTS AND OTHER PROCESS MAY BE MADE BY REGISTERED OR CERTIFIED MAIL ADDRESSED TO SUCH PERSON AT THE ADDRESS SET FORTH IN SECTION
15 OF THIS WARRANT AND THAT SERVICE SO MADE SHALL BE DEEMED COMPLETED UPON THE EARLIER OF ACTUAL RECEIPT THEREOF OR THREE (3) DAYS
AFTER DEPOSIT IN THE U.S. MAILS, PROPER POSTAGE PREPAID.

 

    	10

    	 

    

18.Severability. If any one
or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable
in any respect for any reason, the validity, legality and enforceability of any such provision in every other respect and of the
remaining provisions hereof shall not be in any way impaired, unless the provisions held invalid, illegal or unenforceable shall
substantially impair the benefits of the remaining provisions hereof. The parties hereto further agree to replace such invalid,
illegal or unenforceable provision of this Warrant with a valid, legal and enforceable provision that will achieve, to the extent
possible, the economic, business and other purposes of such invalid, illegal or unenforceable provision.

 

19.WAIVER OF JURY TRIAL. BECAUSE
DISPUTES ARISING IN CONNECTION WITH COMPLEX FINANCIAL TRANSACTIONS ARE MOST QUICKLY AND ECONOMICALLY RESOLVED BY AN EXPERIENCED
AND EXPERT PERSON AND THE PARTIES WISH APPLICABLE STATE AND FEDERAL LAWS TO APPLY (RATHER THAN ARBITRATION RULES), THE PARTIES
DESIRE THAT DISPUTES ARISING HEREUNDER OR RELATING HERETO BE RESOLVED BY A JUDGE APPLYING SUCH APPLICABLE LAWS. THEREFORE, TO ACHIEVE
THE BEST COMBINATION OF THE BENEFITS OF THE JUDICIAL SYSTEM AND OF ARBITRATION, THE PARTIES HERETO WAIVE ALL RIGHT TO TRIAL BY
JURY IN ANY ACTION, SUIT OR PROCEEDING BROUGHT TO RESOLVE ANY DISPUTE, WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE, AMONG
THE COMPANY AND HOLDER ARISING OUT OF, CONNECTED WITH, RELATED TO, OR INCIDENTAL TO THE RELATIONSHIP ESTABLISHED IN CONNECTION
WITH, THIS WARRANT OR ANY OF THE OTHER TRANSACTION DOCUMENTS OR THE TRANSACTIONS RELATED HERETO OR THERETO.

 

20.Entire Agreement. This Warrant,
together with the Purchase Agreement, contains the entire agreement among the parties with respect to the subject matter hereof
and supersedes all prior and contemporaneous agreements or understandings with respect thereto.

 

[signature page follows]

 

    	11

    	 

    

IN WITNESS WHEREOF, the Company has caused
this Warrant to be signed by its duly authorized officer, duly attested by its authorized officer, as of the date first set forth
above.

 

 

	 	
        Manhattan Pharmaceuticals, Inc.

         

        By:

        Name: ____________________________

        Title: _____________________________

         

	
        ATTEST:

         

        By:

        Name: ____________________________

        Title: _____________________________

         
	 

    	[Signature Page]

    	 

    

 

NOTICE OF EXERCISE

 

	To:	
        Manhattan Pharmaceuticals, Inc.

        787 Seventh Ave.

        48th Floor

        New York, New York 10019

1.The undersigned,
pursuant to the provisions of the attached Warrant, hereby elects to exercise this Warrant with respect to ________ shares of Common
Stock (the “Exercise Amount”). Capitalized terms used but not otherwise defined herein have the meanings ascribed
thereto in the attached Warrant.

 

2.Please issue a certificate or certificates
representing the shares issuable in respect hereof under the terms of the attached Warrant, as follows:

 

	 	
         

        (Name of Record Holder/Transferee)

 

and deliver
such certificate or certificates to the following address:

 

	 	
        (Address of Record Holder/Transferee)

         

3.If the Exercise Amount is less than
all of the shares of Common Stock purchasable hereunder, please issue a new warrant representing the remaining balance of such
shares, as follows:

	 	
         

        (Name of Record Holder/Transferee)

and deliver
such warrant to the following address:

 

	 	
        (Address of Record Holder/Transferee)

         

 

	Date:	
        Name of Record Holder

         

        _______________________________________

         

        By:

        Name: ____________________________

        Title: _____________________________

 

    	[Notice of Exercise]CONFIDENTIAL TREATMENT REQUESTED. Confidential portions of
this document have been redacted and have been separately filed with the Commission.

 

Exhibit No. 10.35

                                                                                                                                        
 

EXCLUSIVE LICENSE AGREEMENT

 

BY AND AMONG

 

GTC
BIOTHERAPEUTICS, INC.,

 

LFB
BIOTECHNOLOGIES S.A.S.,

 

LFB/GTC
LLC

 

and

 

TG THERAPEUTICS, INC.

 

January, 30th , 2012

 

CONFIDENTIAL

 

    	 

    	 

    

 

TABLE OF CONTENTS

 

	 	 	Page
	 	 	 
	1.	DEFINITIONS	2
	 	 	 
	2.	LICENSE GRANTS; EXCLUSIVITY	18
	 	 	 
	 	2.1	License	18
	 	2.2	Right to Sublicense	20
	 	2.3	No Other Rights	21
	 	2.4	Exclusivity	21
	 	 	 	 
	3.	DEVELOPMENT OF PRODUCTS	22
	 	 	 	 
	 	3.1	Development Program	22
	 	3.2	Development Diligence	23
	 	3.3	Preparation of Development Plan	23
	 	3.4	Compliance	24
	 	3.5	Process Development services; Supply of Compounds for Development	24
	 	3.6	Use of Proprietary Materials	24
	 	 	 	 
	4.	REGULATORY ACTIVITIES	25
	 	 	 	 
	 	4.1	Responsibility for Regulatory Filings	25
	 	4.2	Disclosure; Right of Access	25
	 	4.3	Disclosure of Certain Events	26
	 	4.4	Communication with Regulatory Authorities in the LICENSOR Commercialization Territory	26
	 	 	 	 
	5.	COMMERCIALIZATION OF PRODUCTS	26
	 	 	 	 
	 	5.1	Commercialization Plan	26
	 	5.2	Responsibility for Commercialization of Products	27
	 	5.3	Commercialization Diligence	27
	 	5.4	Failure to Satisfy Commercialization Diligence Obligations	27
	 	5.5	Failure to achieve Sales Targets	28
	 	5.6	Compliance	29
	 	5.7	No Unauthorized Sales	29
	 	5.8	Records; Reports	29
	 	5.9	Supply of Product for Commercialization	29
	 	5.10	Product Recalls	30
	 	5.11	Grant of Commercialization Option to LICENSOR	30
	 	 	 	 
	6.	SUPPLY OF THE COMPOUND	31
	 	 	 	 
	 	6.1	Supply of LFB-R603 for Development and Commercialization	31
	 	6.2	Supply of TG20 for Development and Commercialization	32
	 	6.3	Contractual conditions for Process Development Services and supply of Compounds for Development	33

 

    	i

    	 

    

 

	7.	PAYMENTS	33
	 	 	 	 
	 	7.1	Issuance of Equity	33
	 	7.2	Milestone Payments	33
	 	7.3	Payment of Royalties; Royalty Rates; Sublicense Royalties; Accounting and Records	34
	 	 	 	 
	8.	TREATMENT OF CONFIDENTIAL INFORMATION; PUBLICITY	37
	 	 	 	 
	 	8.1	Confidentiality	37
	 	8.2	Publicity	39
	 	8.3	No Use of Name	39
	 	8.4	Publications and Presentations	39
	 	 	 	 
	9.	INTELLECTUAL PROPERTY RIGHTS	39
	 	 	 	 
	 	9.1	LICENSOR Intellectual Property Rights	39
	 	9.2	Improvement	39
	 	9.3	Joint Improvement	40
	 	9.4	Patent Coordinators	40
	 	9.5	Notice; Inventorship	41
	 	 	 	 
	10.	FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS	41
	 	 	 	 
	 	10.1	Patent Filing, Prosecution and Maintenance	41
	 	10.2	Enforcement and Defense	43
	 	10.3	Trademark Prosecution and Registration	45
	 	 	 	 
	11.	TERM AND TERMINATION	46
	 	 	 	 
	 	11.1	Term	46
	 	11.2	Termination	46
	 	11.3	Consequences of Termination of Agreement	46
	 	11.4	Surviving Provisions	48
	 	 	 	 
	12.	REPRESENTATIONS AND WARRANTIES	49
	 	 	 	 
	 	12.1	Mutual Representations and Warranties	49
	 	12.2	Additional Representations of LICENSOR	49
	 	12.3	Additional Representations of TG	50
	 	 	 	 
	13.	INDEMNIFICATION; INSURANCE	50
	 	 	 	 
	 	13.1	Indemnification of LICENSOR by TG	51
	 	13.2	Indemnification of TG by LICENSOR	51
	 	13.3	Conditions to Indemnification	52
	 	13.4	Insurance	52
	 	13.5	Warranty Disclaimer	52
	 	13.6	No Warranty of Success	52
	 	13.7	Limited Liability	52
	 	 	 	 
	14.	MISCELLANEOUS	53
	 	 	 	 
	 	14.1	Disputes; Consent to Jurisdiction	53
	 	14.2	Notices	53

  

    	ii

    	 

    

 

	 	14.3	Governing Law	54
	 	14.4	Competition Law	55
	 	14.5	Binding Effect	55
	 	14.6	Headings	55
	 	14.7	Counterparts	55
	 	14.8	Amendment; Waiver	55
	 	14.9	No Third Party Beneficiaries	55
	 	14.10	Section 365(n)	55
	 	14.11	Purposes and Scope	56
	 	14.12	Assignment and Successors	56
	 	14.13	Force Majeure	56
	 	14.14	Interpretation	56
	 	14.15	Integration; Severability	57
	 	14.16	Further Assurances	57

 

 

 

    	iii

    	 

    

 

EXCLUSIVE LICENSE AGREEMENT

 

This EXCLUSIVE LICENSE
AGREEMENT (this “Agreement”) is entered into as of January 30th, 2012 (the “Effective Date”)
by and among GTC Biotherapeutics, Inc., a Massachusetts corporation with a principal place of business at 175 Crossing Boulevard,
Framingham, Massachusetts 01701 (“GTC”), LFB Biotechnologies S.A.S., a company organized under the laws of France
with a principal place of business at 3 avenue des Tropiques, B.P. 305-Les Ulis- 91958, Courtaboeuf Cedex, France (“LFB”),
LFB/GTC LLC, a New York limited liability company with a principal place of business at 175 Crossing Boulevard, Framingham, Massachusetts
01701 (“LFB/GTC” and, collectively with GTC and LFB, “LICENSOR”) and TG Therapeutics, Inc.,
a Delaware corporation with a principal place of business at 787 Seventh Avenue, 48th Floor, New York, New York 10019
(“TG”). Each of TG and LICENSOR is sometimes referred to individually herein as a “Party”
and collectively as the “Parties.”

 

RECITALS

 

WHEREAS, LICENSOR is
engaged in research and development activities on new pharmaceutical products derived from or incorporating recombinant plasma
proteins and/or monoclonal antibodies;

 

WHEREAS, LICENSOR is
the owner, licensee or sublicensee of certain patents, technology and material related to the Compounds (as such term
is defined below);

 

WHEREAS, prior to the
signature of the present Agreement, LICENSOR has entered into the license agreements related to the Compound, including:

 

		-	A license agreement with Dr Hadam on an anti CD 20 monoclonal antibody, CAT 13.6.E12 and the hybridoma
cell-line producing such murine antibody

		-	A license agreement with Pharming on the casein promoter

		-	A license agreement with Start/Viagen on the cloning and nuclear transfer technology

 

WHEREAS, pursuant to
the terms and conditions of that certain Option Agreement by and between LICENSOR and TG, dated April 29, 2011 (the “Option
Agreement”),TG was granted an exclusive option (the “Option”) to obtain an exclusive license under
the Licensed Patent Rights and Licensed Technology (as such terms are defined below) to research, develop, use, import, offer to
sell and sell the Compounds in the Field of Use (as such term is defined below) upon the satisfaction by TG of a certain Option
Condition (as defined in the Option Agreement);

 

    	 

    	 

    

 

Whereas,
the Option Condition has been satisfied and TG has timely exercised the Option in accordance with the terms of the Option Agreement;

 

Whereas,
pursuant to Section 3.4 of the Option Agreement, the Parties have agreed, upon exercise of the Option, to enter into a license
on the terms and subject to the conditions set forth in this Agreement; and

 

Whereas,
in furtherance of such transaction, LICENSOR and TG have also agreed to enter into a Development Services and Manufacturing Agreement,
Commercial Supply Agreement and Stock Purchase Agreement on the terms described herein.

 

NOW, THEREFORE, in
consideration of the mutual covenants contained herein, and for other good and valuable consideration, the Parties hereto, intending
to be legally bound, hereby agree as follows:

 

1.      DEFINITIONS

 

Whenever used
in this Agreement with an initial capital letter, the terms defined in this Article 1 shall have the meanings specified.

 

1.1           “Acceptance”
means, with respect to a Drug Approval Application filed for a Product (a) in the United States, the receipt of written notice
from the FDA in accordance with 21 CFR 314.101(a)(2) that such Drug Approval Application is officially “filed” and
(b) in the European Union, receipt of written notice of acceptance by the EMA of such Drug Approval Application for filing under
the centralized European procedure in accordance with any feedback received from European Regulatory Authorities; provided, that,
if the centralized filing procedure is not used, then Acceptance shall be determined upon the acceptance of such filing for such
Drug Approval Application by the applicable Regulatory Authority in any Major Market Country.

 

1.2           “Adverse
Event” means any untoward medical occurrence in a human clinical trial subject or in a patient who is administered a
Compound or Product, whether or not considered related to the compound or product, including any undesirable sign (including abnormal
laboratory findings of clinical concern), symptom or disease associated with the use of a Compound or Product, as defined more
fully in 21 CFR §312.32.

 

1.3           “Affiliate”
means, with respect to any Person, any other Person that, directly or indirectly, controls, or is controlled by, or is under common
control with, such Person. For purposes of this definition, “control” means (a) ownership of more than fifty percent
(50%) of the shares of stock entitled to vote for the election of directors in the case of a corporation, or more than fifty percent
(50%) of the equity interests in the case of any other type of legal entity, (or such lesser maximum percentage permitted in those
jurisdictions where majority ownership by foreign entities is prohibited); (b) status as a general partner in any partnership;
or (c) any other arrangement whereby a Person controls or has the right to control the board of directors of a corporation or equivalent
governing body of an entity other than a corporation.

 

    	2

    	 

    

 

1.4           “Agreement”
means this exclusive license agreement and its Exhibit and Schedules listed in the table of content.

 

1.5           
“Annual Net Sales” means, with respect to any Calendar Year, the aggregate amount of Net Sales for such Calendar
Year.

 

1.6           “Anticipated
Date of Receipt of Marketing Authorization” means, the date of receipt of Marketing Authorization from EMA set forth
in the Development Plan (Appendix XX)

 

1.7           “API”
means the active pharmaceutical ingredient that is intended to be used in the Manufacture of any Product.

 

1.8           “Applicable
Laws” means any national, international, federal, state or local laws, treaties, statutes, ordinances, rules and regulations,
including any rules, regulations, guidance or guidelines of Regulatory Authorities having the binding effect of law, or of any
national securities exchanges or securities listing organizations or other government authorities other than Regulatory Authorities,
that are in effect from time to time during the Term and applicable to a particular activity hereunder.

 

1.9           “Background
Patent Rights” means any Patent Rights that are Controlled by LICENSOR, other than Licensed Patent Rights, containing
one or more claims that could Cover any Compound or Product (including its Manufacture or its formulation or a method of its delivery
or of its use). For the sake of clarity, the Background Patent Rights existing as of the Effective Date are listed on Schedule
4.

 

1.10         “BLA”
means (a) any Biologic License Application, as defined in the FDCA and regulations promulgated thereunder, or any successor
application or procedure required to market and sell a Product in the Territory; and (b) all supplements and amendments to the
foregoing.

 

1.11         
“Branding” means all matters relating to the branding of any Product, including any matters related to the selection
of any trademarks, brand names, product logos, branding colors, trade dress, positioning and key messages to be incorporated into
Promotional Materials used for any Product in the Territory.

 

1.12         “Business
Day” means any day other than a Saturday or Sunday on which banking institutions in New York, New York are open for business.

 

1.13         “Calendar
Quarter” means the period beginning on the Effective Date and ending on the last day of the calendar quarter in which
the Effective Date falls, and thereafter each successive period of three (3) consecutive calendar months ending on March 31, June
30, September 30 or December 31; provided, that, the final Calendar Quarter shall end on the last day of the Term.

 

    	3

    	 

    

 

1.14         “Calendar
Year” means the period beginning on the Effective Date and ending on December 31 of the calendar year in which the Effective
Date falls, and thereafter each successive period of twelve (12) months commencing on January 1 and ending on December 31; provided,
that, the final Calendar Year shall end on the last day of the Term.

 

1.15         “Challenge”
means any challenge to the validity or enforceability of any of the Licensed Patent Rights before any administrative, judicial
or other governmental authority, court, tribunal or arbitration panel, including by (a) filing a declaratory judgment action in
which any of the Licensed Patent Rights is alleged to be invalid or unenforceable; (b) citing prior art pursuant to 35 U.S.C. §301,
filing a request for re-examination of any of the Licensed Patent Rights pursuant to 35 U.S.C. §302 and/or §311, or provoking
or becoming a party to an interference with an application for any of the Licensed Patent Rights pursuant to 35 U.S.C. §135;
or (c) filing or commencing any re-examination, opposition, cancellation, nullity or similar proceedings against any of the Licensed
Patent Rights in any country.

 

1.16         “Change
of Control” means, with respect to TG, a transaction or series of related transactions (including any merger, consolidation,
share exchange, reorganization or combination) involving TG and any Third Party that results in (a) the holders of outstanding
voting securities of TG immediately prior to such transaction ceasing to represent at least fifty percent (50%) of the combined
outstanding voting power of TG or of the surviving or continuing entity immediately after such transaction or series of transactions;
(b) any Third Party (other than a trustee or other fiduciary holding securities under an employee benefit plan) becoming the beneficial
owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of TG (including as a single Third
Party all persons who in concert or act together as a “group” for purposes of acquiring shares of TG, in accordance
with Section 13(d) of the Securities Act of 1934) (other than an investment transaction by an entity not engaged in the pharmaceutical
or biotechnology business, the purpose of which is to raise capital for TG); or (c) the sale or other disposition to a Third Party
of all or substantially all of TG’s assets or business to which this Agreement relates. 

 

1.17         “Clinical
Data” means any and all data (together with all Clinical Trial reports and the results of analyses thereof) derived or
generated from any Clinical Trial of a Compound or Product or from testing of subjects or the analysis of samples used in any such
Clinical Trial.

 

1.18         “Clinical
Trial” means, collectively, any Phase 1 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial, as applicable.

 

1.19         “Combination
Product” means a single product that includes, in combination with a Product, one or more therapeutically-active ingredients
other than a Product that are sold in a single package or as a unit at a single price either as a fixed dosage form or as separate
dosage forms.

 

1.20         “Commercialization”
or “Commercialize” means any and all activities directed to the offering for sale and sale of a Product after
Marketing Authorization has been obtained with respect to such Product, including, (a) activities directed to marketing, promoting,
detailing, distributing, Manufacturing, importing, selling and offering to sell such Product; (b) interacting with Regulatory Authorities
regarding any of the foregoing; and (c) seeking Pricing Approvals and Reimbursement Approvals for such Product (d) Post Approval
Clinical Trials. When used as a verb, “to Commercialize” and “Commercializing” means to engage
in Commercialization and “Commercialized” has a corresponding meaning.

 

    	4

    	 

    

 

1.21         “Commercialization
Plan” means, with respect to any Product, the written report prepared by TG pursuant to Section 5.1 and submitted to
LICENSOR for its review that (a) describes the Commercialization activities that TG reasonably expects to conduct with respect
to such Product in the Territory, and (b) sets forth (i) a non-binding estimate of projected sales of such Product in the Territory,
and (ii) a summary of all actual sales of such Product in the Territory, as such report may be amended or updated by TG from time
to time. Without limiting the foregoing, each Commercialization Plan shall include, without limitation, (a) demographics and market
dynamics, market strategies, a marketing plan (including advertising, detailing forecasts, Pricing strategies pertaining to discounts
and sales forecasts) for the Territory; (b) specific Commercialization and marketing objectives, projected milestones, resource
allocation requirements and activities to be performed over such period (including all anticipated Clinical Trials) (collectively,
the “Commercialization Targets”); (c) a timeline for such activities, including the estimated launch date(s)
in the Territory; (d) a sales and expense forecast (including at least five (5) years of estimated sales and expenses in terms
of both volume and value) for the Territory; (e) Manufacturing plans and the expected product profile; and (f) the expected Regulatory
Filings to be required and prepared, and the expected timetable for making such Regulatory Filings.

 

1.22         
“Commercially Reasonable Efforts” means, with respect to the activities of TG, and/or its Affiliates, Sublicensees,
Distributors, in the Development or Commercialization, as the case may be, of a particular Compound and/or Product, the level of
efforts and resources typically used and expected from a pharmaceutical company of similar size for the development or commercialization
of products of comparable market potential, taking into account all relevant factors including, as applicable, the stage of development,
observed efficacy and safety of the Product and relative to Competitive Products in the marketplace, actual or anticipated Regulatory
Authority approved labeling, the nature and extent of market exclusivity (including patent coverage, regulatory exclusivity and
competitiveness of alternative products), the cost and likelihood of obtaining Marketing Authorization, the actual or projected
profitability, and the reasonably expected and actual pricing, reimbursement and formulary status. For purposes of clarity, Commercially
Reasonable Efforts shall be determined on a market-by-market and Indication-by-Indication basis for a particular Compound and/or
Product, and it is anticipated that the level of effort may be different for different markets and may change over time, reflecting
changes in the status of the Compound or Product and the market(s) involved.

 

1.23         “Competitive
Entity” means any Third Party that (a) together with its Affiliates and subsidiaries, collectively had worldwide sales
of ethical pharmaceutical products, in the Calendar Year that preceded the Change of Control, of at least One Billion Dollars (U.S.
$1,000,000,000), and (b) on the date of such Change of Control is actively working on any research program involving the
expenditure of funds or the application of full time equivalents in the aggregate amount of at least $500,000 per Calendar Year
involving a Competitive Program.

 

1.24         “Competitive
Products” means any anti CD 20 monoclonal antibody for use in the Field

 

    	5

    	 

    

 

1.25         “Competitive
Program” means any program that involves the research, development or commercialization of any (a) transgenically-derived
chimeric monoclonal antibody or (b) cell-product anti CD 20 monoclonal antibody for use in the Field.

 

1.26         “Completion”
means, with respect to any Clinical Trial, the date on which all material data reasonably expected to be derived therefrom has
been generated and the final study report with respect thereto has been finalized. 

 

1.27         “Compounds”
means, collectively, (i) TG20 and/or (b) LFB-R603.

 

1.28         “Confidential
Information” means with respect to each Party, all information, Technology and Proprietary Materials that is (i) TG Background
Technology, in the case of TG and (ii) Licensed Technology, in the case of LICENSOR, and, that, in any case, is disclosed or provided
by or on behalf of such Party (the “Disclosing Party”) to the other Party (the “Receiving Party”)
or to any of the Receiving Party’s employees, consultants, Affiliates or sublicensees; provided, that, none of the foregoing
shall be Confidential Information if: (A) as of the date of disclosure, it is known to the Receiving Party or its Affiliates as
demonstrated by contemporaneous written documentation maintained in the ordinary course of business, other than by virtue of a
prior confidential disclosure to such Receiving Party; (B) as of the date of disclosure it is in the public domain, or it subsequently
enters the public domain through no fault of the Receiving Party; (C) it is obtained by the Receiving Party from a Third Party
having a lawful right to make such disclosure free from any obligation of confidentiality to the Disclosing Party; or (D) it is
independently developed by or for the Receiving Party without reference to or use of any Confidential Information of the Disclosing
Party as demonstrated by contemporaneous written documentation maintained in the ordinary course of business. For purposes of clarity,
(a) unless excluded from Confidential Information pursuant to the preceding sentence, any scientific, technical, manufacturing
or financial information of a Party that is disclosed through any report (including any audit report) shall constitute Confidential
Information of the Disclosing Party; (b) all Clinical Data produced by TG in connection with the Development of a Compound or Product
and/or in the conduct of Clinical Trials shall be Confidential Information of TG; and (c) any combination of Confidential Information
shall not be considered in the public domain or in the possession of the Receiving Party merely because individual elements of
such Confidential Information are in the public domain or in the possession of the Receiving Party unless the combination and its
principles are in the public domain or in the possession of the Receiving Party.

 

1.29         “Control”
or “Controlled” means (a) with respect to Technology (other than Proprietary Materials) or Patent Rights, the
possession by a Party (or an Affiliate of such Party, as applicable) of the right to grant a license or sublicense to such Technology
or Patent Rights as provided herein without violating the terms of any agreement or arrangement with, infringing the Patent Rights
of, or misappropriating the proprietary or trade secret information of, any Third Party and without violating any Applicable Laws
and (b) with respect to Proprietary Materials, the possession by a Party of the right to supply such Proprietary Materials to the
other Party as provided herein without violating the terms of any agreement or arrangement with any Third Party and without violating
any Applicable Laws. Notwithstanding the foregoing, no Party (or Affiliate of a Party, as applicable) shall be deemed to Control
any Technology, Proprietary Materials or Patent Rights solely by virtue of the license grants set forth in this Agreement.

 

    	6

    	 

    

 

1.30         
“Cover” or “Covered” means, with respect to a Product, that the manufacture, use or sale
of such Product in a particular country by an unlicensed Third Party would infringe a Valid Claim.

 

1.31         “Development”
or “Develop” means, with respect to a Product, (a) all non-clinical and clinical drug development activities
that are undertaken after the Effective Date up to and including the date of obtaining of Marketing Authorization of such Product
to obtain including (i) the conduct of Clinical Trials, toxicology and pharmacology testing, test method development and stability
testing, process development (“Process Development” as defined below in Section 1.84) (including the Manufacture of
validation and engineering batches), formulation development, delivery system development, quality assurance and quality control
development, analytical method development, human clinical studies and regulatory affairs activities and statistical analysis and
report writing; (ii) the preparation of Clinical Trial design and operations; (iii) preparing and filing Drug Approval Applications,
and (b) all activities related to Manufacturing Development and (c) any and all other activities that may be necessary or useful
to obtain Regulatory Approval. When used as a verb, “Developing” means to engage in Development and “Developed”
has a corresponding meaning.

 

1.32         “Development
Plan” means, with respect to the Compound and/or any Product, the non-binding written plan for, and estimated budget
applicable to, the Development activities anticipated to be conducted by TG for the Compound and/or Product, as such written plan
may be amended, modified or updated in accordance with Section 3.1.3. Topics that may be covered in the plan, (a) the Clinical
Trials (including investigator-initiated clinical trials) that are expected to be conducted and the expected timeline for conducting
such Clinical Trials; (b) the expected Drug Approval Applications to be required and prepared, and the expected timetable for making
such Drug Approval Applications; (c) the pharmaceutical development and Manufacturing strategy, proposed timelines for Manufacturing,
acquisition, Manufacturing scale-up, formulation, filling and/or shipping of the Product;

 

1.33         “Development
Program” means (a) the Development activities to be conducted by TG during the Term with respect to the Compounds and
(b) the Development activities to be conducted by LICENSOR during the Term under the Development Services and Manufacturing Agreement
as set forth in the Development Plan and defined in 3.1.2.

 

1.34         “Distributor”
means any Person that purchases Product from TG or any of TG’s Affiliates or Sublicensees for purposes of resale of Product
to end users in the Territory (including any wholesalers, pharmacists or hospitals).

 

    	7

    	 

    

 

1.35         “Divest”
means, with respect to a Competitive Program, a divestiture of such Competitive Program to a Third Party by sale, license or otherwise;
provided, that, if such divestiture is made by TG by way of one or more licenses or sublicenses, (a) TG and its Affiliates shall
not hold or retain any rights with respect to such Competitive Program other than (i) the right to receive license fees, milestone
payments and royalties on sales of products (or other sources of revenue, including with respect to Manufacturing) with respect
to such Competitive Program, (ii) the right to defend claims of infringement, (iii) the right to assert claims of infringement
against Persons who may infringe its intellectual property rights with respect to products with respect to such Competitive Program
and (iv) the right to otherwise control filings and patent term extensions connected with any licensed or sublicensed Patent Rights,
and (b) TG and its Affiliates are not consulted with respect to, and do not otherwise participate in, any decisions (other than
those described in clauses (ii), (iii) and (iv) above), or otherwise collaborate with any Third Party, with respect to (x) the
commercialization of products with respect to such Competitive Program or (y) the commercial strategy with respect to products
with respect to such Competitive Program.

 

1.36         “Drug
Approval Application” means, with respect to a Product in the Territory, an application for Marketing Authorization for
such Product in the Territory. For purposes of clarity, Drug Approval Application shall include, without limitation, (a) an NDA
or BLA (for US) or MAA (for Europe); (b) a counterpart of an NDA or BLA, sNDA or sBLA, or MAA in any country or region in the Territory;
and (c)and all supplements and amendments to the foregoing.

 

1.37         “EMA”
means the European Medicines Agency or any successor agency or authority thereto.

 

1.38         “Excluded
Application” means (a) any application involving the determination or monitoring of (i) the presence or absence of a
disease; (ii) the stage, progression or severity of a disease or (iii) the effect on a disease of a particular treatment; (b) any
application involving the selection of patients for a particular treatment; and (c) any in vitro applications or uses.

 

1.39         “Executive
Officer” means the Chief Executive Officer of LFB and the Chief Executive Officer of TG.

 

1.40         “FDA”
means the United States Food and Drug Administration or any successor agency or authority thereto.

 

1.41         “FDCA”
means the United States Federal Food, Drug, and Cosmetic Act, as amended.

 

1.42         “Field”
means the treatment, control, mitigation, prevention and/or cure of all human therapeutic Indications. For purpose of clarity,
the definition of “Field” shall not include any Excluded Application.

 

1.43         “First
Commercial Sale” means, with respect to a Product in the Territory, the first sale, transfer or disposition for value
to an end user of such Product in the Territory after Marketing Authorization for such Product has been received in the Territory;
provided, that, a First Commercial Sale shall not include: (a) any sale to an Affiliate, Sublicensee or Distributor (unless
the Affiliate, Sublicensee or Distributor is the last entity in the distribution chain of the Product), (b) any use
of a Product in Clinical Trials, pre-clinical studies or other research or development activities, or (c) the disposal or transfer
of Products for a bona fide charitable purpose, including compassionate use or named patient use.

 

    	8

    	 

    

 

1.44         “Force
Majeure” means any occurrence beyond the reasonable control of a Party that (a) prevents or substantially interferes
with the performance by such Party of any of its obligations hereunder and (b) occurs by reason of any act of God, flood, fire,
explosion, earthquake, strike, lockout, labor dispute, casualty or accident, or war, revolution, civil commotion, act of terrorism,
blockage or embargo, or any injunction, law, order, proclamation, regulation, ordinance, demand or requirement of any government
or of any subdivision, authority or representative of any such government.

 

1.45         “GLP”
means the then-current Good Laboratory Practice Standards promulgated or endorsed by the FDA or, in the case of foreign jurisdictions,
comparable regulatory standards promulgated or endorsed by the applicable Regulatory Authority.

 

1.46         “GMP”
means current Good Manufacturing Practices that apply to the Manufacture of API and/or the clinical or commercial supply of Products,
including, without limitation, the United States regulations set forth under Title 21 of the United States Code of Federal Regulations,
parts 210 and 211, as amended from time-to-time, as well as all applicable guidance published from time-to-time by the FDA or,
in the case of foreign jurisdictions, comparable regulatory standards promoted or endorsed by the applicable Regulatory Authority
and the International Conference on Harmonization Guidelines ICHQ7A Good Manufacturing Practice Guidance for API or the principles
and guidelines of Good Manufacturing Practices for Medicinal Products as defined with EC Directive 2003/94/EC and associated EC
Guide to Good Manufacturing Practice.

 

1.47         “Good
Clinical Practice” or “GCP” means the applicable regulations or guidance relating to the design, conduct,
recording, and reporting of Clinical Trials that involve the participation of human subjects, when generating Clinical Trial data
intended to be submitted to Regulatory Authorities, as set forth in the FDCA and any regulations or guidance documents promulgated
thereunder, including but not limited to the ICH E6 consolidated guidance on Good Clinical Practice.

 

1.48         “Hadam
License Agreement” means that certain License Agreement, dated August 15, 2006, by and between LFB and Dr. Martin Hadam.

 

1.49         Hatch-Waxman
Act” means the Drug Price Competition and Patent Term Restoration Act of 1984, as amended.

 

1.50         “IND”
means: (a) an Investigational New Drug Application, as defined in the FDCA and regulations promulgated thereunder, or any successor
application or procedure required to initiate clinical testing of a Product in humans in the Territory; and (b) all supplements
and amendments to the foregoing. 

 

1.51         “Indication”
means each separate and distinct disease, illness and/or condition, interruption, cessation or disorder of a particular bodily
function, system, tissue type or organ, or sign or symptom of any such items or conditions, regardless of the severity, frequency
or route of any treatment, dosage strength or patient class, for which Regulatory Approval is being sought.

 

    	9

    	 

    

 

1.52         Investigator’s
Brochure” means a compilation of preclinical and clinical data with respect to a new investigational drug that is proposed
for filing with a Regulatory Authority and used to provide information to clinical investigators and Regulatory Authorities.

 

1.53         “Joint
Improvement” means any Program Technology that is (a) jointly conceived, developed or reduced to practice by one or more
employees of, or consultants to, TG and/or its Affiliates, Sublicensees, Distributors and one or more employees of, or consultants
to, LICENSOR or (b) conceived , developed, or reduced to practice solely by one or more employees of, or consultants to TG resulting
from the use by TG in any material respect of the Licensed Technology, Licensed Patent Rights, Background Patent Right or LICENSOR
Materials.

 

1.54         “Joint
Patent rights” means any Patent Rights related to Joint Improvements.

 

1.55         “Knowledge”
or “Known” means, with respect to a Party, the actual knowledge of the Executive Officer or of
any executive officer (as defined for purposes of Section 14 of the Securities Exchange Act of 1934, as amended) of such Party.

 

1.56         “LFB-R603”
means the cell-culture produced chimeric monoclonal antibody described on Schedule 3 attached hereto and incorporated herein
by reference.

 

1.57         “Licensed
Patent Rights” means any Patent Rights that are Controlled by LICENSOR during the Term and that (a) contain one or more
claims that Cover any Compound or Product; and (b) are necessary or useful for TG to Develop and/or Commercialize
any Compound or Product in the Field and in the Territory. For purposes of clarity, (a) the Licensed Patent Rights existing as
of the Effective Date are listed on Schedule 4 attached hereto and (b) Schedule 4 shall be updated by LICENSOR by
written notice to TG on an annual basis during the Term to include any additional
patents and patent applications not previously listed; provided, that, the exclusion of a patent or patent application from Schedule
4 shall not be deemed to be a conclusive indication of whether that patent or application is or should be considered a “Licensed
Patent Right” for purposes of this Agreement.

 

1.58         “Licensed
Technology” means any Technology that is Controlled by LICENSOR during the Term and that (a) relates to any Compound
or Product and (b) is necessary or useful for TG to Develop, and/or Commercialize any Compound or Product in the Field and in the
Territory.

 

1.59         “Licensed
Trademark” means the trademarks listed in Schedule 7, together with all goodwill associated therewith.

 

1.60         “LICENSOR
Commercialization Option Period” has the meaning set forth in 5.11.

 

1.61         “LICENSOR
Commercialization Territory” means France and Belgium.

 

1.62         “LICENSOR
Materials” means any Proprietary Materials that are Controlled by LICENSOR and used by LICENSOR, or provided by LICENSOR
for use, in the Development Program.

 

    	10

    	 

    

 

1.63         “LICENSOR
Improvement” means any Program Technology that is conceived or first reduced to practice by employees of, or consultants
to, LICENSOR alone or jointly with any Third Party, without the use, in any material respect, of any TG Materials or Joint Improvement.

 

1.64         “Major
European Market Country” means the United Kingdom, Germany, France, Italy or Spain.

 

1.65         “Manufacture”
or “Manufacturing” or “Manufactured” means all activities related to
the production of any API or Product, including the manufacture, receipt, inspection, storage and handling of materials, and the
manufacture, processing, purification, packaging, labeling, warehousing, quality control testing (including in-process release
and stability testing), shipping and release of API or Product.

 

1.66         “Manufacturing
Development” means, with respect to any API or Product, all activities related to the optimization of a commercial-grade
Manufacturing process for the Manufacture of such API or Product including, test method development and stability testing, formulation,
validation, productivity, trouble shooting and next generation formulation, process development, Manufacturing scale-up, strain
improvements, development-stage Manufacturing, and quality assurance/quality control development.

 

1.67         “Marketing
Authorization” means, with respect to any Product, the Regulatory Approval required by Applicable Laws to market and
sell such Product for use for any Indication in the Field in the Territory,. For purposes of clarity, (a) “Marketing Authorization”
in the United States means final approval of an NDA or BLA, or, sNDA or sBLA (depending on the Product) permitting marketing of
the applicable Product in interstate commerce in the United States; and (b) “Marketing Authorization” in the
European Union means marketing authorization for the applicable Product granted either by a Regulatory Authority in any Major Market
European Country or by the EMA pursuant to Council Directive 2001/83/EC, as amended, or Council Regulation 2309/93/EEC, as amended
For the avoidance of doubt, Marketing Authorization does not include Pricing Approvals and Reimbursement Approvals.

 

1.68         “NADA”
means a New Animal Drug Application required by the US Food and Drug Administration for the use of any genetically engineered animal
in which the gene coding for the API is stably integrated in the genome of the animal

 

1.69         “NDA”
means (a) any New Drug Application, as defined in the FDCA and regulations promulgated thereunder, or any successor application
or procedure required to market and sell a Product in the Territory; and (b) all supplements and amendments to the foregoing.

 

    	11

    	 

    

 

1.70      “Net
Sales” means the gross amount billed or invoiced by TG or any of its Affiliates or Distributors (each, a “Seller”)
to Third Parties in the Territory for sales or other dispositions or transfers for value of Products less (a) allowances for trade,
quantity and cash discounts actually allowed and taken; (b) freight, transportation, insurance, postage charges and customs duties
included on a Seller’s bill or invoice or as a separate item; (c) credits, rebates, allowances, and amounts repaid due to
returns, recalls or government regulations, including allowances for uncollectible amounts and/or bad debts on previously sold
Products; (d) retroactive price reductions that are actually allowed or granted; (e) sales taxes, excise taxes, value-added taxes
and other taxes (other than income taxes) levied on the invoiced amount; and (f) duties, tariffs and other governmental charges.
In addition, Net Sales are subject to the following:

 

(i)          Net
Sales shall not include sales or transfers between TG and any of its Affiliates, Sublicensees or Distributors unless such Affiliate,
Sublicensee or Distributor is the end user of the Product.

 

(ii)         If
any Seller effects a sale, disposition or transfer of a Product to a Third Party in a particular country other than on customary
commercial terms or for non-monetary consideration, the Net Sales of such Product to such Third Party shall be deemed to be “the
fair market value” of such Product. For purposes of this subsection (ii), “fair market value” means the value
that would have been derived had such Product been sold as a separate product to another customer in the country concerned on customary
commercial terms.

 

(iii)        For
purposes of this Agreement, “sale” shall mean any transfer or other distribution or disposition, but shall not include
transfers or other distributions or dispositions of Product at no charge for academic research, preclinical, clinical, or regulatory
purposes (including the use of a Product in Clinical Trials) or in connection with patient assistance programs or other charitable
purposes or to physicians or hospitals for promotional purposes (including free samples to a level and in an amount which is customary
in the industry and/or which is reasonably proportional to the market for such Product).

 

(iv)        For
the purposes of determining royalty rates and the royalties payable on Combination Products, Net Sales of Product shall be calculated
by multiplying the Net Sales of the Combination Product by the fraction A/A+B, where A is the average selling price, during the
royalty paying period in question, of the Product sold separately in the country in which the sale of the Combination Product is
made, and B is the average selling price, during the royalty period in question, of the other active ingredients or components
sold separately.  In the event that such average selling price cannot be determined for both Product and all other active
ingredients and components included in the Combination Product, Net Sales for purposes of determining payments under this Agreement
shall be calculated by multiplying the Net Sales of the Combination Product by the fraction C/(C+D) where C is the standard fully-absorbed
cost of the Product portion of the combination, and D is the standard fully-absorbed cost of the other active ingredient or component
included in the Combination Product, as determined by TG using its standard accounting procedures consistently applied. In the
event that the standard fully-absorbed cost of the Product and/or the other active ingredients or components included in such Combination
Product cannot be determined, for the purposes of determining royalties payable hereunder, the Parties shall negotiate in good
faith to determine an appropriate commercial value for all the components in the Combination Product and calculate Net Sales of
such Combination Product accordingly.

 

    	12

    	 

    

 

1.71         “Patent
Rights” means the rights and interests in and to issued patents and pending patent applications (which, for purposes
of this Agreement, include certificates of invention, applications for certificates of invention and priority rights) in any country
or region, including all provisional applications, substitutions, continuations, continuations-in-part, divisions, renewals, all
letters patent granted thereon, and all reissues, re-examinations and extensions thereof, and all foreign counterparts of any of
the foregoing.

 

1.72         “Person”
means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited
liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization,
including a government or political subdivision, department or agency of a government.

 

1.73         “Phase
1 Clinical Trial” means a human clinical trial conducted for a Product in any country that would satisfy the requirements
of 21 CFR 312.21(a), as amended (or its foreign equivalent).

 

1.74         “Phase
2 Clinical Trial” means a human clinical trial conducted for a Product for any Indication that would satisfy the requirements
of 21 CFR 312.21(b), as amended (or its foreign equivalent) and is intended to explore one or more doses, dose response, and duration
of effect, and to generate initial evidence of clinical activity and safety for such Product in the target patient population.

 

1.75         “Phase
3 Clinical Trial” means a pivotal human clinical trial conducted for a Product for any Indication that would satisfy
the requirements of 21 CFR 312.21(c), as amended (or its foreign equivalent) and is intended to confirm with statistical significance
the efficacy and safety of such Product with respect to a particular Indication, and is performed to obtain Marketing Authorization.

 

1.76         
“Pivotal Clinical Trial” means (a) a Phase 3 Clinical Trial or, (b) a Phase 2 Clinical Trial to the extent:
(i) in the United States, the protocol for that Phase 2 Clinical Trial shall have been reviewed by the FDA under its current Special
Protocol Assessment Guidelines (or equivalent guidelines issued in the future), and any comments from the FDA on that protocol
are incorporated in the final protocol for that Phase 2 Clinical Trial or are resolved to the FDA’s satisfaction as evidenced
by further written communications from the FDA; or (ii) a process with a comparable result – acceptance of a Phase 2 Clinical
Trial protocol as “potentially pivotal” – has occurred with the EMA/CHMP in the European Union; or (iii) based
on the results of that Phase 2 Clinical Trial, either the FDA or the EMA has determined that the Phase 2 Clinical Trial can be
considered as a pivotal clinical trial for purposes of obtaining Marketing Authorization.

 

1.77         “Post
Approval Clinical Trials” means any Phase 4 clinical trial and/or any clinical trial undertaken after any Marketing Approval
is granted such as Investigator sponsored study.

 

1.78         Pricing”
means the determination of Product pricing at all levels, including the Product list price (also referred to as Wholesale Acquisition
Cost) and the net price in which the Product is offered to purchasers and payers (including both private sector and government
entities).

 

    	13

    	 

    

 

1.79         “Pricing
Approval” means, with respect to a Product in the Territory, any pricing approvals, guidance or recommendations reasonably
necessary to market such Product in the Territory. 

 

1.80         “Process
Development” means with respect to a Product, all activities related to process development of API or Product, including
the(a) raw materials selection, (b) manufacturing development, (c) test method development of raw materials, (d) in-process
products, (e) intermediate products, API and Product, (f) formulation development, (g) stability studies of raw material, buffers,
intermediates products, API and Product, (h) viral safety steps development and validation, (i) process robustness and process
validation, (j) analytical method validation for quality controls of raw materials, intermediates, API and Product, (k) shipment
validation, (l) container closure study, (m) leachable and extractable study, (n) cleaning development and validation, (o)
column lifetime study, (p) filing support for regulatory submissions.

 

1.81         “Product”
means any pharmaceutical or medicinal item, substance, formulation or dosage that is comprised of, or contains, a Compound (whether
or not such Compound is the sole active ingredient).

 

1.82         “Product
Improvement” means any Program Technology related to or concerning the Product and/or Licensed Technology, whether or
not patentable, copyrightable or otherwise protectable under any intellectual property rights.

 

1.83         “Program
Technology” means any Technology or Proprietary Material that is conceived and first reduced to practice (actually or
constructively), by TG and/or its Affiliates or jointly by the Parties, or by any Sublicensee or by any Distributors, whether or
not patentable, in the conduct of the Development Program and/or in connection with the Commercialization of Products.

 

1.84         “Proprietary
Materials” means any tangible chemical, biological or physical materials that (a) are furnished
by or on behalf of one Party to the other Party in connection with this Agreement, whether or not specifically designated as proprietary
by such Transferring Party, or (b) that are otherwise conceived or reduced to practice by TG in the conduct of the Development
Program and/or in connection with the Commercialization of Products.

 

1.85         
“Regulatory Approval” means, with respect to the Territory, any approval, product and establishment license,
registration or authorization of any Regulatory Authority required for the Manufacture, use, storage, importation, exportation,
transport or distribution of a Product in the Territory, including any Marketing Authorization, Reimbursement Approval and Pricing
Approval .

 

1.86         “Regulatory
Authority” means any national, international, regional, state or local regulatory agency, department, bureau, commission,
council or other governmental entity with authority over the distribution, importation, exportation, Manufacture, production, use,
storage, transport, clinical testing, marketing, Pricing or sale of a Product in the Territory, including the FDA and the EMA.

 

    	14

    	 

    

 

1.87         “Regulatory
Filings” means, collectively: (a) all INDs, NDAs, BLAs, NADAs, MAAs establishment license applications, Drug Master Files,
and all other similar filings (including, without limitation, counterparts of any of the foregoing in the Territory); (b) all supplements
and amendments to any of the foregoing; (c) all data and other information contained in, and correspondence relating to, any of
the foregoing; and (d) any and all orphan drug applications. 

 

1.88         “Reimbursement
Approval” means, with respect to a Product in the Territory, any pricing reimbursement registration or listing
on formularies and all approval necessary to an optimal introduction of the Product on the market.

 

1.89         “Royalty
Term” means with respect to each Product in each country in the Territory, the period beginning on the date of First
Commercial Sale of such Product in such country and ending on the later of (a) the expiration of the last to expire Valid Claim
of the Licensed Patent Rights or TG Program Patent Rights in such country that Covers the composition of matter, Manufacture, use
or sale of such Product, and (b) fifteen (15) years from the date of the First Commercial Sale of such Product in such country.

 

1.90         Sales
Target means that proportion of the total patient market for the Product provided to Licensor by TG and expressed as either
a percentage or calculated number of vials of the Product as set forth in Schedule 3.

 

1.91         “Serious
Adverse Event” means any untoward medical occurrence that, at any dose, results in death, is life-threatening,
requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity,
or is a congenital anomaly/birth defect, as more full defined in 21 CFR § 312.32.

 

1.92         “Significant
Development Event” means any of the following material Development events, a summary of which shall be included
in any Development Report : (a) any material interaction and/or written correspondence between TG and any Regulatory Authority
with respect to the Compound or a Product; (b) any material event with respect to any Clinical Trial involving the Compound and/or
a Product, including any such event that is ongoing as of the date of the applicable Development Report, or is reasonably expected
to occur or be initiated within twelve (12) months of the date of the applicable Development Report; and (c) any material result
obtained in the conduct of any Clinical Trial involving the Compound and/or a Product during the period covered by the Development
Report. For purposes of clarity, all information provided to LICENSOR with respect to Significant Development Events, shall be
deemed to be Confidential Information of TG. For purposes of this definition, “material” shall be defined as any event
and/or result which have had or may have a significant impact on the activities and timelines defined in the Development plan
of each Product.

 

1.93         sBLA”
means a Supplemental Biologic License Application, as defined in the FDCA and applicable regulations promulgated thereunder.

 

1.94         “sNDA”
means a Supplemental New Drug Application, as defined in the FDCA and applicable regulations promulgated thereunder.

 

    	15

    	 

    

 

1.95         “Sublicensee”
means any Third Party to which TG grants a sublicense in accordance with Section 2.2.

 

1.96         “Sublicense
Agreement” means any agreement by and between a Party and a Sublicensee which is entered into in accordance with Section
2.2.

 

1.97         “Sublicense
Income” means any royalties on Sublicensee Net Sales received by Licensee from its Sublicensees, excluding (a)
payments made by a Sublicensee in consideration of the issuance of equity or debt securities of Licensee to the extent that the
price paid for such equity does not exceed the then fair market value of such equity as determined by TG’s Board of Directors
in good faith and separately confirmed by LICENSOR (it being understood that any amounts paid in excess of fair market value shall
be deemed to be Sublicense Income) and (b) payments made by a Sublicensee which are used to support or fund research and development
activities to be undertaken by TG or any of its Affiliates after the effective date of the Sublicense Agreement pursuant to a budget
for sponsored research which has been agreed to with the Sublicensee and based on full-time equivalent or other cost-accounting
methodologies that are consistent with then current industry practices.

 

1.98         “Sublicense
Royalties” means, in any country in which a Sublicense Agreement is executed by TG, a payment equal to the greater of
(a) *
percent (*%) of the amount of Sublicense Income received by TG from such Sublicense
Agreement in such country and (b) * percent (*%)
of the Annual Net Sales of Products by such Sublicensee in such country.

 

1.99         “Technology”
means, collectively, all inventions, discoveries, improvements, trade secrets and proprietary information and methods, whether
or not patentable or patented, including without limitation: (a) methods of Manufacture or use of, and structural and functional
information pertaining to, chemical compounds; (b) compositions of matter, data, formulations, processes, techniques, know-how
and results (including any negative results) and (c) results of clinical trials, pre-clinical trials and other Development activities.

 

1.100“Territory”
means any country or jurisdiction in the world.

 

1.101“TG20”
means the transgenic-derived chimeric monoclonal antibody described more fully on Schedule 5 attached hereto and incorporated
herein by reference.

 

1.102
“TG Materials” means any Proprietary Materials that are Controlled by TG and used by TG, or provided by TG for
use, in the Development Program.

 

1.103
“Third Party” means (a) with respect to TG, any Person other than TG and its respective Affiliates, Sublicensees
and Distributors and (b) with respect to LICENSOR, any Person other than its Affiliates.

 

 

*Confidential material redacted and filed separately
with the Commission.

 

    	16

    	 

    

 

1.104“Valid
Claim” means any claim of (a) an issued unexpired patent that (i) has not been finally cancelled, withdrawn, abandoned
or rejected by any administrative agency or other body of competent jurisdiction, (ii) has not been permanently revoked, held invalid,
or declared unpatentable or unenforceable in a decision of a court or other body of competent jurisdiction that is unappealable
or unappealed within the time allowed for appeal, (iii) has not been rendered unenforceable through terminal disclaimer or otherwise,
and (iv) is not lost through an interference proceeding that is unappealable or unappealed within the time allowed for appeal;
or (b) a claim of a pending Patent application, which claim has not been abandoned or finally disallowed without the possibility
of appeal.

 

Additional Definitions.
In addition, each of the following definitions shall have the respective meanings set forth in the section of this Agreement indicated
below:

 

	Definition	 	Section
	 	 	 
	Action	 	10.2.1(a)(ii)
	Anticipated Approval Notice	 	5.11.1(a)
	Claims	 	13.1
	Commercialization Report	 	5.6
	Competitive Program Transaction	 	2.4.2(a)
	Competitive Program Transaction Notice	 	2.4.2(a)
	Development Report	 	3.3.1
	Diligence Failure Notice	 	5.3
	Disclosing Party	 	1.24
	Dispute	 	14.1
	Effective Date	 	Preamble
	Filing Party	 	10.1.3
	LFB	 	Preamble
	LFB/GTC	 	Preamble
	LICENSOR	 	Preamble
	LICENSOR Commercialization Option	 	5.1.1(b)
	LICENSOR Commercialized Product	 	5.1.1(b)
	LICENSOR Indemnities	 	13.1
	ICH	 	3.3
	Indemnified Party	 	13.3
	Indemnifying Party	 	13.3
	Infringement	 	10.2.1(a)(i)
	Infringement Notice	 	10.2.1(a)(i)
	Losses	 	13.1
	Manufacturing and Supply Agreement	 	3.4
	Non-Publishing Party	 	8.4
	Option	 	Recitals
	Option Agreement	 	Recitals
	Party/Parties	 	Preamble
	Patent Coordinator	 	9.4
	Promotional Materials	 	5.9
	Publishing Party	 	8.4
	Recall	 	5.10
	Receiving Party	 	1.24
	Recipient Party	 	3.5
	Results	 	8.4

 

    	17

    	 

    

 

	Definition	 	Section
	 	 	 
	Seller	 	1.60
	Stock Purchase Agreement	 	7.1
	TG	 	Preamble
	TG Diligence Failure Notice	 	5.3
	TG Indemnities	 	13.2
	Term	 	11.1
	Transferring Party	 	3.5

 

2.          LICENSE
GRANTS; EXCLUSIVITY

 

2.1          License.

 

2.1.1           Grant
of License to TG. 

 

Subject to the
terms and conditions of this Agreement, LICENSOR hereby grants to TG an exclusive (including with respect to LICENSOR and their
respective Affiliates), worldwide, royalty-bearing license or sublicense (with respect to Licensed Technology and/or Licensed Patent
Rights licensed by Third Parties to LICENSOR), including the right to grant sublicenses as provided in Section 2.2, under the Licensed
Technology and Licensed Patent Rights to Develop the Compounds or Products as part of the Development Program and to Commercialize,
use, have used, Manufacture, have Manufactured, supply, sell, offer to sell, import, have imported, market, and otherwise Commercialize
Products in the Field.

 

For the avoidance of
doubt, the right granted by LICENSOR to TG to Manufacture or have Manufactured the Product in the Field is subject to the terms
and conditions of Sections 3.5 and 5.9.

 

In addition,
LICENSOR hereby grants to TG a non-exclusive, worldwide, fully paid up license or sublicense, including the right to grant sublicenses
as provided in Section 2.2, under the Background Patent Rights to Develop the Compounds or Products as part of the Development
Program and to Commercialize, use, have used, Manufacture, have Manufactured, and supply, sell, offer to sell, import, have imported,
market, and otherwise Commercialize Products in the Field.

 

2.1.2           Reversion.
Should TG or its Sublicensee(s) stop the Development or the Commercialization of any Product, any and all license granted
to TG by LICENSOR in respect of such Product shall automatically revert back to LICENSOR (including licenses granted according
to Sections 2.1.1 and 2.1.4). In such case, TG commits to grant to LICENSOR an exclusive, royalties free license or sublicense
(with respect to Rights licensed by Third Parties to TG), including the right to grant sublicenses, under the all Patent Rights
Controlled by TG, Joint Improvement and Joint Patent Right necessary or useful for LICENSOR to Develop such Compounds or Product
and/or use, have used, Manufacture, have Manufactured, supply, sell, offer to sell, import, have imported, market, and otherwise
Commercialize such Products in the Field and in the Territory.

 

    	18

    	 

    

 

For the avoidance
of doubt, the Development of a Product shall be considered stopped if the aggregate amount spent by TG or its Sublicensee(s) on
the Development activities, up to the filing of the Drug Approval Application, is less than (*)*$
per year for such Product for more than * years.

 

For the avoidance
of doubt, the Commercialization of a Product shall be considered as stopped if, after all Regulatory Approvals and Reimbursement
Approvals have been granted at least in the US or in one of Major European Market Country when:

 

		-	the aggregate amount spent by TG or its Sublicensee(s) on the Commercialization activities is less
than $*per year for such Product; and

 

		-	or, a minimum of * percent (*
%) of Sales Target has not been recorded for over a period of more than * (*)
years;

 

2.1.3        Disclosure
of Technology.  LICENSOR shall provide prompt written notice to TG of all Licensed Patent Rights or Licensed Technology
Controlled by LICENSOR and their respective Affiliates that come under the Control of LICENSOR or their respective Affiliates after
the Effective Date during the Term.

 

2.1.4   Grant
of License to Licensed Trademark. 

 

(a)          Ownership
of Trademarks. TG hereby acknowledges that LICENSOR has already performed
a Trademarks research and has registered the Licensed Trademarks. However, TG is entitled to use and register any other trademarks,
on LICENSOR behalf, and at TG own cost, for Development and Commercialization purposes. 

 

(b)          Grant
of License. Subject to the terms and conditions of this Agreement, LICENSOR hereby grants to TG a royalty bearing
an exclusive license to use the Licensed Trademark solely
for the purpose of registering, using, Commercializing, importing, exporting, selling, offering for sale, and having sold
the Product in the Field in the Territory on the terms and subject to the conditions set forth in this Agreement.

 

(c)          Covenants
of TG. TG hereby agrees that all use of the Licensed Trademark by TG, and any goodwill associated with the use of the Licensed
Trademark by TG, shall inure to the benefit of LICENSOR. TG hereby agrees that nothing in this Agreement shall give TG any right,
title or interest in the Licensed Trademark other than the right to use the Licensed Trademark in accordance with this Agreement.
TG further agrees that it will not: (i) oppose or assist any Third Party in opposing any application for registration, re-registration
or renewal of the Licensed Trademark; ii) apply for or otherwise seek (or assist any Third Party in applying for or otherwise seeking)
complete or partial revocation, cancellation, invalidation or removal of the Licensed Trademark from any register or (iii) challenge
or bring (or assist any Third Party in challenging or bringing) any proceeding or action in relation to the use or ownership of
the Licensed Trademark.

 

 

*Confidential material redacted and filed separately
with the Commission.

 

    	19

    	 

    

 

(d)          Registration
of Licensed Trademark. LICENSOR shall have the sole right to apply for registration of the Licensed Trademark in the Territory
to the extent such registration has not already been obtained by LICENSOR at the Effective Date and for paying all applicable fees,
including all registration and application fees and renewal fees. TG agrees that it will not apply for the registration of the
Licensed Trademark (or any mark confusingly similar thereto) anywhere in the world.

 

(e)          Use
of Licensed Trademark. TG shall use the Licensed Trademark solely (i) in the manner specified in this Agreement and (ii)
in connection with the Product and not for any other goods or services. TG agrees not to use any other trademark or service mark
in combination with the Licensed Trademark without the prior written consent of GTC. TG, at its sole cost and expense, will provide
to LICENSOR representative samples of all products, product packaging, literature, brochures, signs, and advertising materials
prepared by TG which bear, display, or include any reference to the Licensed Trademark, and TG shall obtain the written approval
of LICENSOR with respect to all such materials prior to the use thereof. TG will not distribute or otherwise use any samples or
materials or other media bearing or displaying the Licensed Trademark unless and until LICENSOR has notified TG in writing of LICENSOR’s
approval, which approval shall not be reasonably withheld.

 

(f)          Notice.
TG shall promptly notify LICENSOR (i) of any claim, threat, lawsuit, filing, or other notice or allegation of infringement of which
it is aware regarding TG’s use of the Licensed Trademark and/or (ii) if it becomes aware of the existence of any Third Party
applications to register anywhere in the world any mark or name which consists of or incorporates the Licensed Trademark. LICENSOR
shall have the sole right, but not the obligation, to bring infringement, unfair competition, or other claims or proceedings involving
the Licensed Trademark and TG hereby acknowledges and agrees that it shall have no such right. If requested by LICENSOR, TG shall
cooperate with LICENSOR in connection with any such action.

 

2.2          Right
to Sublicense.

 

2.2.1           Sublicense.
TG shall have the right to grant sublicenses under the licenses granted to it under Section 2.1.1 to any Sublicensee; with LICENSOR
prior written notification provided, that, (a) the terms of each such sublicense shall be consistent with the rights and obligations
of TG under the Agreement; (b) it shall be a condition of any such sublicense that such Sublicensee agrees to be bound by the terms
of this Agreement applicable to the Development and Commercialization of Products in the Field in the Territory; (c) TG shall provide
LICENSOR with a copy of any such Sublicense Agreement within ten (10) days of the execution of each such Sublicense Agreement;
and (d) TG shall not be relieved of its obligations pursuant to this Agreement as a result of such sublicense, except to the extent
such obligations are satisfactorily performed by any such sublicense.

 

2.2.2           Grant
of Rights to Distributors. TG or any of its Affiliates and Sublicensees shall have the right, with LICENSOR prior written
notification, to appoint one or more Distributors for Products in the Territory. TG shall provide LICENSOR with a copy of each
such agreement with any Distributor within ten (10) days of execution of such agreement.

 

    	20

    	 

    

 

2.3          No
Other Rights.

 

2.3.1           TG
shall have no rights to use or otherwise exploit Licensed Technology, Licensed Patent Rights, or LICENSOR Proprietary Materials,
and LICENSOR shall have no rights to use or otherwise exploit TG Technology, TG Patent Rights or TG Proprietary Materials, in each
case, except as expressly set forth in this Agreement.

 

2.4          Exclusivity.

 

2.4.1       Exclusivity
Obligation.  During the Term of this Agreement, TG shall not, and shall cause each of its Affiliates to not, conduct
any activity, either on its own, or with, for the benefit of, or sponsored by, any Third Party, that, in any case, involves the
research, development or commercialization of any other anti CD 20 monoclonal antibody, or any compound that embodies or is derived
from any anti CD 20 monoclonal antibody, for use in the Field that is competitive with or adversely affects the Development or
Commercialization of any of the Compounds or Products, except hereunder in connection with the research, Development and/or the
Commercialization of the Compounds and Products. Notwithstanding the foregoing, at TG’s request, LICENSOR may allow TG to
Develop and Commercialize all combinations with the Compounds and Products which would be benefit in improving the Development
and/or the Commercialization of the Compounds and Products, such consent to not be unreasonably withheld.

 

2.4.2      Competitive
Program Transaction.  

 

(a)          Notice.
If at any time during the Term, TG grants a sublicense or other rights to any Third Party to utilize any Technology or Patent Rights
Controlled by TG or any of its Affiliates for the Development or Commercialization of any of the Compounds or Products, or TG undergoes
a Change of Control, or if TG or any of its Affiliates acquires all or substantially all of the assets or common stock of a Third
Party (whether by asset or stock purchase, merger, consolidation, share exchange or other similar transaction) and, in any such
case, such Third Party or any of such Third Party’s Affiliates (in the case of a Third Party Sublicensee or a Third Party
acquirer of TG), has a Competitive Program (a “Competitive Program Transaction”), TG shall provide LICENSOR
with prompt written notice describing such Competitive Program Transaction in reasonable detail
which shall include a description of the nature of such Competitive Program
(the “Competitive Program Transaction Notice”). Such Competitive Program Transaction Notice shall be provided
by TG prior to execution of such agreement, if permitted under Applicable Laws and not prohibited by the terms of any agreement
between TG or any of its Affiliates and any Third Party, and otherwise as soon as practicable thereafter and, in any event, not
later than promptly following the consummation of the transaction contemplated by such agreement.

 

(b)          Meeting
of the Parties. As soon as practicable following LICENSOR’ receipt of any Competitive Program Transaction Notice,
the Parties shall meet to discuss
whether, notwithstanding any provision hereof, such
Competitive Program would continue following such Competitive Program Transaction. In any such meeting the Parties will review
any restrictions applicable to such Competitive Program that may prevent its combination with this Agreement, and other issues
that may impact the potential combination of such Competitive Program with this Agreement. 

 

    	21

    	 

    

 

(c)          Integration
of Competitive Program. If
TG and LICENSOR mutually agree that such Competitive Program may be integrated into this Agreement, then within *
(*)
*
after such determination the Parties shall agree upon an amendment to this Agreement that will provide either (X) (i) that
each compound or product that is part of the Competitive Program would be deemed to be a Compound,
whether or not such compound or product meets the standards or criteria hereunder for a Compound and (ii) the
Parties’ rights and obligations under this Agreement will apply in all relevant respects to any such deemed Compounds
(including the payment of the milestones, royalties and Sublicense Royalties set forth in
this Agreement) or (Y) that the Development and Commercialization diligence standards of this Agreement shall be revised to ensure
that the effort and resources that the Third Party applies (or TG, if TG is the surviving entity) applied to the Competitive Program
shall be equally applied to the Development and Commercialization of the Compounds and Products.  

 

(d)          Termination/Divesting
of Competitive Program. If the Parties are unable to reach agreement on the
terms pursuant to which the integration of any Competitive Program into this Agreement would occur, TG shall have an additional
*
(*)*
during which it shall determine whether to (i) terminate the Competitive Program or (ii) Divest itself of the Competitive Program.
If TG notifies LICENSOR in writing that it will terminate such Competitive Program, TG shall promptly terminate such Competitive
Program as quickly as possible with due regard for patient safety and the rights of any subjects that are participants in any clinical
studies relating to such Competitive Program and Applicable Laws, and in any event within *
(*)*
after its delivery of such written notice to LICENSOR. If TG notifies LICENSOR in writing that it will Divest itself of the Competitive
Program, then it shall do so as promptly as practicable but in any event on or before *
(*)*
from the date of such notice; provided, that, during the period during which such Divestiture is pending, TG shall maintaining
separate teams working on such Competitive Program and this Agreement. If TG does not notify LICENSOR in writing at the conclusion
of the *
(*)
*
period provided above that TG will terminate or Divest itself of such Competitive Program, or if TG does so notify LICENSOR but
fails to terminate or Divest the Competitive Program within the periods provided above, LICENSOR shall have the right to immediately
terminate this Agreement by providing written notice to TG.

 

3.          DEVELOPMENT
OF PRODUCTS

 

For the sake of clarity, in this Section
3, TG means TG, and where applicable, its Affiliates, Sublicensees and Distributors.

 

3.1          Development
Program. 

 

3.1.1           Objective
of Development Program. The objective of the Development Program shall be the Development by TG of the Compounds and Products
in the Field in order to obtain Marketing Authorization for such Products in the Field in the Territory as promptly as practicable.

 

 

*Confidential material redacted and filed separately
with the Commission.

 

    	22

    	 

    

 

3.1.2           Responsibility
for Development. TG shall have the sole right and responsibility for, and shall have full control and authority
over, at its sole cost and expense (including without limitation all costs attributable to the Manufacture and supply of Product
for the conduct of Clinical Trials), the Development of Products in the Territory, including conducting all Development activities
and establishing the methods and means by which it performs such activities under this Agreement. TG shall have the right to engage
Third Party contractors to perform any of its Development activities in the Territory, subject to the execution by each such Third
Party contractor of an agreement containing provisions with respect to confidentiality and assignment of Technology that are consistent
with, and comparable in scope to, Articles 7 and 8 of this Agreement. Notwithstanding the foregoing, from time to time during the
Term, TG may request in writing that LICENSOR perform certain Development activities as part of the Development Program. If TG
requests that LICENSOR provide Development activities, LICENSOR will promptly provide a timeline and budget for providing such
services and will use Commercially Reasonable Efforts to provide such services in accordance with the timeline and budget. Such
services shall be provided in accordance with the terms set forth in the development services and manufacturing agreement (the
“Development Services and Manufacturing Agreement”) which shall be attached in Exhibit A as soon as it is executed
by the Parties. As described more fully in the Services Agreement, LICENSEE shall provide such services, and TG shall pay for such
services, based on LICENSOR’S *;
provided, that, (a) during the first six (6) months following the Effective DateLICENSOR shall provide such services free of charge
until such date as an aggregate of * ($*)
of such services have been provided (*) and (b) for the remainder of the term of
the Services Agreement, TG shall pay LICENSOR a service fee for such services equal to LICENSOR’S *
percent (*%).

 

3.2           Development
Diligence.

 

TG, and/or its Affiliates,
Sublicensee, Distributors shall use Commercially Reasonable Efforts during the Term to (a) conduct Development activities with
respect to the Compounds and Products and (b) commit such resources (including employees, consultants, contractors, facilities,
equipment and materials) as it deems necessary to conduct such Development activities. Without limiting the foregoing, TG’s
efforts described in this Section 3.2 shall comply with the diligence obligations set forth in the Hadam License Agreement.

 

3.3           Preparation
of Development Plan. 

 

An initial Development
Plan shall be prepared by TG for each Product and submitted to the LICENSOR for its information no later than *
(*)* after the Effective Date and
attached hereto as Schedule 1. During the period commencing on and after such date and continuing for the remainder of the
Term, TG shall prepare and provide to the LICENSOR an additional Development Plans detailing any amendments, modifications and/or
updates to any existing Development Plan, within * (*)
* of the end of each Calendar Year. TG shall seek health authority scientific advice
to determine the pivotal studies deemed necessary for product registration at the earliest possible time. The advice received should
be reflected in updated Development Plans. In the event of any conflict between the terms of the Development Plan and the terms
and conditions of this Agreement, the terms and conditions of this Agreement shall prevail.

 

 

*Confidential material redacted and filed separately
with the Commission.

 

    	23

    	 

    

 

3.4           Compliance.

 

TG and/or its Affiliates,
Sublicensee, Distributors shall perform its obligations under the Development Program in good scientific manner and in compliance
in all material respects with all Applicable Laws. For purposes of clarity, with respect to each Development activity performed
that will or would reasonably be expected to be submitted to a Regulatory Authority in support of a Regulatory Filing or Drug Approval
Application, TG shall not willfully fail to comply in all material respects with GLPs, GMPs or Good Clinical Practices (or, if
and as appropriate under the circumstances, International Conference on Harmonization (“ICH”) guidance or other
comparable regulation and guidance of any Regulatory Authority in the Territory).

 

3.4.1           Records;
Reports. TG and/or its Affiliates, Sublicensees, Distributors shall (a) maintain records of its activities under the Development
Program in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, which shall fully and
properly reflect all work performed and results achieved in the performance of the Development Program and (b) keep LICENSOR regularly
informed of the progress of its efforts to Develop Products in the Territory, including without limitation, providing LICENSOR
with an annual development report (each, a “Development Report”) (to be delivered with each annual update to
the Development Plan) that summarizes: (a) significant Development activities conducted during the preceding Calendar Year and
results obtained with respect to Compounds and Products (including the status of all Clinical Trials), (b) Significant Development
Events applicable to the Compounds and/or Products, (c) a summary of all Program Technology conceived or reduced to practice by
TG over such period, (d) a non-binding estimate of the expected timing of any milestone events with respect to Products and (e)
such other information that TG has in its possession as may be reasonably requested from time to time by LICENSOR. The Development
Plan and each Development Report shall be deemed TG Confidential Information. Following the commencement of Commercialization,
Development Reports will no longer be required and will be replaced by the annual Commercialization Report as described in Section
5.7.

 

3.5           Process
Development services; Supply of Compounds for Development.

 

LICENSOR’s and
TG’s rights and responsibilities pertaining the Process Development and the supply of the Compound for the Development shall
be governed by Section 6 below.

 

3.6           Use
of Proprietary Materials.

 

From time to time during
the Term, either Party (the “Transferring Party”) may supply the other Party (the “Recipient Party”) with
Proprietary Materials of the Transferring Party for use in the Development Program. In connection therewith, each Recipient Party
hereby agrees that (a) it shall not use such Proprietary Materials for any purpose other than exercising its rights or performing
its obligations hereunder; (b) it shall use such Proprietary Materials only in compliance with all Applicable Laws; (c) it shall
not transfer any such Proprietary Materials to any Third Party without the prior written consent of the Transferring Party, except
for the transfer of Products for use in Clinical Trials or as otherwise expressly permitted hereby; (d) the Recipient Party shall
not acquire any right, title or interest in or to such Proprietary Materials as a result of such supply by the Transferring Party;
and (e) upon the expiration or termination of the Development Program, the Recipient Party shall, if and as instructed by the Transferring
Party, either destroy or return any such Proprietary Materials that are not the subject of the grant of a continuing license hereunder.

 

    	24

    	 

    

 

4.          REGULATORY
ACTIVITIES

 

For the sake of clarity, in this Section
4, TG means TG, and where applicable, its Affiliates, Sublicensees and Distributors.

 

4.1           Responsibility
for Regulatory Filings.

 

Subject to the remainder
of this Article 4, (a) TG shall have the sole right and responsibility, at its sole cost and expense, for preparing and filing
all Regulatory Filings and Drug Approval Applications required to Develop Compounds and Commercialize Products in the Territory
in its own name; (b) all Regulatory Approvals for Products shall be solely owned by TG; and (c) TG shall have the sole right and
responsibility for (i) maintaining all Regulatory Filings and/or Marketing Authorizations and (ii) reporting to any Regulatory
Authority within the Territory all Adverse Events and Serious Adverse Events related to any Product if and to the extent required
by Applicable Laws. To maximize market protection of Product, TG shall file for any orphan drug designations as appropriate within
requisite timeframes prior to the submission of any Marketing Authorization Application. Within twelve (12) months following the
QA approval of the Study Report of the last Clinical Trial as per the Development Program, TG shall file, or cause to be filed,
before the Regulatory Authorities in the Territory, all authorization and registration applications required for the promotion,
marketing, distribution and sale of Product in the Territory. TG shall exercise Commercially Reasonable Efforts to obtain Marketing
Authorizations with respect to the Product. Failure to meet this obligation will be considered a material breach of the Agreement
and LICENSOR shall have the right to terminate the Agreement for breach of TG in accordance with Section 11.2.2.

 

4.2           Disclosure;
Right of Access.

 

Upon request from LICENSOR,
TG shall promptly provide LICENSOR with (a) a list of all sites at which Clinical Trials with respect to Products are being conducted
by or on behalf of TG; (b) copies of all Clinical Trial protocols and Investigator’s Brochures with respect to such Clinical
Trials; and (c) access to all data (including non clinical and Clinical Data), results and information found in TG’s regulatory
files produced by or on behalf of TG, or any of its Affiliates or Sublicensees, in connection with the conduct by TG of Development
activities in its original format, without translation except that translations shall be provided at no charge where such translations
are produced in the ordinary course of business. LICENSOR shall maintain the confidentiality of such data, results and information
and shall only have the right and license to use such data (including Clinical Data), results and information provided by TG under
this Section 4.2 for the performance of its obligations and exercise of its rights under this Agreement,

 

    	25

    	 

    

 

4.3           Disclosure
of Certain Events.

 

The Parties hereby
agree to report to each other all Adverse Events and/or Serious Adverse Events with respect to the Product (whether occurring in
any Clinical Trial conducted with regard to the Product or in connection with the commercialization of the Product in any country),
within timeframes consistent with its reporting obligations under Applicable Laws and in any event, if either Party is actively
conducting a clinical trial under its own IND or commercializing the Product under its own Marketing Authorization, then the other
Party shall report such events no later than three (3) business days for Serious Adverse Event, and quarterly for Adverse Events,
which report shall, in each case, include the circumstances and nature of such Serious Adverse Event or Adverse Event as required
for reporting under Applicable Laws. In addition, to the extent requested by either Party, the other Party shall promptly provide
to the requesting Party any other information or materials that the requesting Party may require to provide to any Regulatory Authority
with respect to any such Adverse Event or Serious Adverse Event. All disclosures made under this Section 4.3 shall be deemed Confidential
Information of the disclosing Party; provided, that, the Party receiving such disclosures may, upon written notice to the disclosing
Party, report the occurrence, circumstances and nature of such Adverse Event and/or Serious Adverse Event to any Regulatory Authority
solely insofar as such reporting is required to comply with Applicable Laws.

 

4.4           Communication
with Regulatory Authorities in the LICENSOR Commercialization Territory.

 

4.4.1           Participation
in Meetings. TG shall use reasonable efforts to provide LICENSOR with at least thirty (30) days advance notice of any meeting
with any Regulatory Authority regarding any Marketing Authorization for any Product in the LICENSOR Commercialization Territory
and LICENSOR may elect to send one (1) person reasonably acceptable to TG to participate as an observer (at LICENSOR’ sole
cost and expense) in such meeting.

 

4.4.2           Access;
Notice of Meetings.  TG shall use reasonable efforts to provide LICENSOR with at least thirty (30) days’ advance
notice of any meeting with any Regulatory Authority in the LICENSOR Commercialization Territory regarding any Drug Approval Application
for Products and/or any such audit or inspection conducted by any Regulatory Authority at any site at which Clinical Trials with
respect to Products are being conducted and LICENSOR may elect to send representatives reasonably acceptable to TG to participate
as an observer in such meeting at LICENSOR’ sole cost and expense.

 

5.          COMMERCIALIZATION
OF PRODUCTS

 

For the sake of clarity, in this Section
5, TG means TG, and where applicable, its Affiliates, Sublicensees and Distributors.

 

5.1           Commercialization
Plan. 

 

The initial Commercialization
Plan shall be prepared by TG and submitted to LICENSOR for information with the Anticipated Approval Notice and attached hereto
as Schedule 2. On and after such date and continuing for the remainder of the Term, additional Commercialization Plans and/or
amendments, modifications and/or updates to the Commercialization Plan, shall be prepared by TG and submitted to LICENSOR for its
review within thirty (30) days of the end of each Calendar Year.

 

    	26

    	 

    

 

5.2           Responsibility
for Commercialization of Products. 

 

Subject to Section
5.11 below, TG shall have the primary right and responsibility for, and shall have primary control and authority over, at its sole
cost and expense, (a) all aspects of the Commercialization of Products in the Field in the Territory including the sole responsibility
for booking sales of Product and for all returns, charge-backs and rebates with respect to Products; and (b) the conduct of all
pre-marketing, marketing, Branding, promotion, sales, distribution, import and export activities (including securing pricing, reimbursement,
sales and marketing and conducting any post-marketing trials or post-marketing safety surveillance and maintaining databases) applicable
to the Commercialization of Products in the Field and in the Territory.

 

5.3           Commercialization
Diligence.  

 

TG shall use Commercially
Reasonable Efforts during the Term to Commercialize Products for all approved Indications in the Field and in the Territory. Without
limiting the foregoing, (a) commencing no later than ninety (90) days prior to the estimated date of First Commercial Sale of the
Product, TG shall conduct pre-marketing activities in the Territory with respect to the Product and (b) following receipt of Marketing
Authorization with respect to the Product in the Territory, TG shall initiate and conduct such promotional activities determined
by TG as may be required to develop a commercial market for, launch and Commercialize the Product (including through direct conduct
with key opinion leaders) in the Territory. Without limiting the foregoing, TG’s efforts described in this Section 5.3 shall
comply with the diligence obligations set forth in the Hadam License Agreement. In addition, TG, shall establish and maintain a
well trained sales force for the Product,( together with a well-trained support staff) adequate to service all the customers of
TG and to keep the sales force knowledgeable and fully informed as to the Product; maintain an effective distribution system for
the Product in the Territory; transport and store the Product to preserve its quality in accordance with pre-determined QA requirements;
obtain and maintain all licenses, approvals and permits in the Territory necessary for TG to perform its obligations under this
Agreement; establish and maintain suitable systems and records to enable a recall of Product in a timely, efficient and accurate
manner and otherwise in accordance with applicable laws and regulations in the Territory; abide by all applicable rules and regulations
relating to sales, marketing and reimbursement; ensure that no Product shipped by TG is adulterated or misbranded; maintain adequate
control over the physical security of the Product; Cause all Affiliates, sublicensees and subcontractors of TG to comply with the
above.

 

5.4           Failure
to Satisfy Commercialization Diligence Obligations. 

 

LICENSOR shall have
the right, in its sole discretion, to provide TG with written notice if it reasonably believes TG has failed to satisfy its Commercialization
diligence obligations under this Agreement (a “TG Diligence Failure”). Such written notice (a “Diligence
Failure Notice”) shall set forth in reasonable detail the nature of the alleged failure and shall request written justification,
in the form of detailed reasons that would support the proposition that TG has satisfied such diligence obligations. TG shall provide
such written justification to LICENSOR within thirty (30) days after receipt of such Diligence Failure Notice and shall identify
any Commercially Reasonable Justifications (as defined below) applicable thereto. If TG fails to provide LICENSOR with a Commercially
Reasonable Justification within such thirty (30) day period TG shall have an additional (90)
day period to cure such failure. During that period a penalty equal to the *
shall accrue on a monthly basis, to the benefit of LICENSOR. Should TG’s failure continue within this additional period,
TG shall continue to pay the penalty abovementioned
and LICENSOR
reserves the right in its discretion to,
in addition to all damages caused in relation thereof, convert the licenses and rights granted under any or all of Section
2.1 from exclusive licenses to non-exclusive licenses only as such licenses and rights apply to such Product.
Should TG’s failure continue within an additional hundred eighty (180) day period, TG shall continue to pay the penalty
abovementioned and LICENSOR reserves
the right in its discretion to, in
addition to any other remedies it may have all damages caused in relation thereof, terminate
any or all of the licenses and rights granted under Section 2.1 hereof with respect to the Product that is the subject of the Diligence
Failure Notice termination or conversion, as the case may be, shall be at the discretion of LICENSOR and be effective immediately
upon issuance by LICENSOR of written notice to TG specifying the remedy that LICENSOR is electing to exercise under this Section
5.4.

 

 

*Confidential material redacted and filed separately
with the Commission.

 

    	27

    	 

    

 

For purposes of this Section 5.4, “Commercially
Reasonable Justification” means the existence or occurrence of one or more of the following events or justifications:
(i) the occurrence of an event of Force Majeure; (ii) the adoption by a Regulatory Authority of any one or more regulations that
become effective after the Effective Date and that materially affect the Development or clinical testing of the Product or the
process for obtaining any Regulatory Approval for the Product; and (iii) the occurrence of any event, condition or circumstance
(including an event, condition or circumstance related to the manufacture or supply of the Product (or any material component thereof)
for clinical studies or a regulatory action by any Regulatory Authority) with respect to the Product (or any material component
thereof) that (A) involves the safety, toxicity, efficacy or pharmacokinetics of the Product or (B) prevents the use of the Product
in humans (including, without limitation, as a result of patent or other blocking rights) and, in the case of clauses (A) or (B)
above, is not attributable to (1) a breach by TG of any obligation under this Agreement, (2) the failure of TG to comply with any
protocol, development plan or Applicable Laws with respect to the development of the Product, or (3) any grossly negligent or willful
act or omission of TG; or (C) that the TG Diligence Failure is caused by TG’s failure to take actions that would be in excess
of Commercially Reasonable Efforts; provided, that, in any such case, TG shall use Commercially Reasonable Efforts to mitigate
the effect and duration of any such acceptable delay with respect to the Product that is the subject of the Diligence Failure Notice.

 

5.5           Failure
to achieve Sales Targets

 

5.5.1           Initial
Period. For the * following the date of First Commercial Sale (the "Initial
Period") TG shall achieve the Sales Target. If TG fails to achieve *
percent (*%) of the Sales Target by completion of the Initial Period, TG shall,
within * (*)*,
pay to LICENSORS a sum equal to *. For purposes of this Agreement, “Commercial
Years” means the period commencing on the date of First Commercial Sale of a Product and ending on the anniversary thereof
and thereafter each successive period of twelve (12) months.

 

5.5.2           Subsequent
Periods. For Commercial Years subsequent to the Initial Period TG shall achieve the Sales Target. If TG fails to achieve
*
percent (*%) of the Sales Target for any Commercial Year subject to the Initial
Period, TG shall, within * (*)*
pay to LICENSOR a sum equal to *.

 

 

*Confidential material redacted and filed separately
with the Commission.

 

    	28

    	 

    

 

In addition to the
above, if TG fails to achieve *
(*%) of the Sales Target for *
(*) * Commercial Years, LICENSOR
shall have the right to terminate this Agreement with respect to countries within the Territory *.
In the case where LICENSOR exercises its rights to terminate this Agreement, LICENSOR shall provide six (6) months prior notice
of termination and purchase back any Product stock held by TG valued at the commercial price. If during the above mentioned 6 month
period, TG achieves * for such six-month period, then TG shall be deemed to have
cured the breach and the termination shall be null and void.

 

5.6           Compliance.

 

TG shall use its Commercially
Reasonable Efforts to Commercialize the Products in compliance in all material respects with all Applicable Laws.

 

5.7           
No Unauthorized Sales.

 

TG shall not, and shall
not permit its Affiliates and not permit Sublicensees or Distributors to, distribute, market, promote, offer for sale or sell the
Product to any Third Party in any country that TG, or its Affiliates, Sublicensees or Distributors, as applicable, reasonably believes
is reasonably likely to engage in an unauthorized distribution, marketing, promotion, or sale of the Product outside the country
of purchase.

 

5.8           Records;
Reports.

 

TG shall (a) maintain
records of its Commercialization activities under this Article 5 in sufficient detail, which shall fully and properly reflect all
work done and results achieved in the Commercialization of Products and (b) following the commencement of Commercialization of
the Products provide LICENSOR with annual written reports (each, a “Commercialization Report”) which shall (i)
summarize TG’s efforts to Commercialize Products, (ii) identify the Regulatory Filings and Drug Approval Applications with
respect to such Product that TG or any of its Affiliates or Sublicensees have filed, sought or obtained in the prior twelve (12)
month period or reasonably expect to make, seek or attempt to obtain in the following twelve (12) month period and (iii) summarize
all Clinical Data generated by TG with respect to Products. Commencing no later than ninety (90) days from the date of receipt
by TG of the first Marketing Authorization for each Product and on each anniversary thereof until the expiration of the Royalty
Term applicable to such Product, each such Commercialization Report shall also include (i) an outline of the key sales and marketing
activities that TG reasonably expects to conduct with respect to Product in the Territory, (ii) a non-binding estimate of projected
sales of Product in the Territory for the subsequent three (3) Calendar Year period and (iii) such additional information that
it has in its possession as may be reasonably requested by LICENSOR regarding the Commercialization of any Product, which request
shall not be made more than once each Calendar Year. The Commercialization Plan and Commercialization Report can be provided as
one document.

 

5.9           Supply
of Product for Commercialization. 

 

LICENSOR’s and
TG’s rights and responsibilities pertaining the supply of the Compound for the Commercialization shall be governed by Section
6 below.

 

 

*Confidential material redacted and filed separately
with the Commission.

 

    	29

    	 

    

 

5.10         Product
Recalls.

 

In the event that any
Regulatory Authority issues or requests a recall or takes similar action in connection with a Product in the Territory, or in the
event TG reasonably believes that an event, incident or circumstance has occurred that may result in the need for a recall, market
withdrawal or other corrective action regarding a Product in the Territory (each, a “Recall”), TG shall promptly
advise LICENSOR thereof by e-mail, telephone or facsimile. Following such notification, TG shall have the sole right to decide,
and have control of, whether to conduct a recall or market withdrawal (except in the event of a recall or market withdrawal mandated
by a Regulatory Authority, in which case it shall be required) or to take other corrective action in the Territory and the manner
in which any such recall, market withdrawal or corrective action shall be conducted; provided, that, TG shall keep LICENSOR reasonably
informed regarding any such Recall. All expenses incurred by TG in connection with any such Recall (including, without limitation,
expenses for notification, destruction and return of the affected Product and any refund to customers of amounts paid for such
Product) shall be the sole responsibility of TG.

 

5.11         Grant
of Commercialization Option to LICENSOR.

 

5.11.1    Exercise
of Commercialization Option.

 

(a)          Notice
of Anticipated Regulatory Approval. TG shall give LICENSOR written notice at least one hundred twenty (120) days prior to the
anticipated date of receipt of Marketing Authorization for a Product for the first Indication by the EMA or the applicable Regulatory
Authority in the LICENSOR Commercialization Territory (the “Anticipated Approval Notice”).

 

(b)          Exercise
of Commercialization Option. Commencing on the date of receipt by LICENSOR of the Anticipated Approval Notice and continuing
for a period of ninety (90) days (such period, the “Product Candidate Option Period”), LICENSOR shall have the
exclusive option (the “LICENSOR Commercialization Option”), in its sole discretion, to have the exclusive
right to Commercialize any Product in the LICENSOR Commercialization Territory by providing written notice to TG, which notice
shall identify the Product (each, such Product, a “LICENSOR Commercialized Product”). If LICENSOR exercises
the Commercialization Option with respect to any Product:

 

(i)          the
Parties shall, within ninety (90) days of the date of such exercise, negotiate and execute a Commercialization and License Agreement
for such LICENSOR Commercialized Product which Commercialization Agreement shall, to the extent possible, be in substantially the
same form as this Agreement;

 

(ii)         the
license granted to TG pursuant to Section 2.1.1 shall be deemed to have been amended such that LICENSOR shall retain the exclusive
right under the Licensed Technology and/or Licensed Patent Rights, including the right to grant sublicenses to its Affiliates,
to Commercialize, use, have used, Manufacture, have Manufactured, supply, sell, offer to sell, import, have imported, market, and
otherwise Commercialize the LICENSOR Commercialized Product in the Field and in the Commercialization Territory;

 

    	30

    	 

    

 

(iii)        the
definition of Territory for purposes of this Agreement shall be deemed to have been amended to specifically exclude the countries
within the LICENSOR Commercialization Territory; and

 

(iv)        TG
shall be deemed to have automatically granted to LICENSOR an exclusive (including with respect to TG and its Affiliates), mirror
royalty-bearing license or sublicense with respect to TG Materials, TG Confidential Information, and all Technology Patent Rights
Controlled by TG (including the right to grant sublicenses under the such Technology and Patent Rights) to Commercialize, use,
have used, supply, sell, offer to sell, import, have imported, market, and otherwise Commercialize the LICENSOR Commercialized
Product in the Field and in the LICENSOR Commercialization Territory. For the avoidance of doubt, the Royalty rate due by LICENSOR
to TG shall be equal to the amount due by TG to LICENSORS on sales recorded in France and Belgium.

 

(c)        Cooperation;
Failure to Reach Agreement. In connection with LICENSOR’S consideration of the exercise of a LICENSOR’s Commercialization
Option with respect to each Product, TG shall provide LICENSOR with any information Controlled by TG and reasonably requested by
LICENSOR that is necessary or useful to LICENSOR in determining whether to exercise such LICENSOR Commercialization Option.

 

6.          SUPPLY
OF THE COMPOUND 

 

6.1           Supply
of LFB-R603 for Development and Commercialization.

 

(a)          Where
the cell culture Manufacturing capacity requested for Manufacturing and supply of LFB R603 for Clinical Trials is less than or
equal to 1 000 liter per batch, LICENSOR shall have the exclusive right and responsibility to provide, directly or indirectly,
Manufacturing services to TG and Manufacture supply of LFB-R603 as required for the Development and Commercialization of LFB-R603
.. In this case, LICENSOR will be responsible for all aspects of Manufacturing and facilities and TG shall be responsible for Process
Development (alone or with LICENSOR through the Development Services and Manufacturing Agreement).

 

LICENSOR
shall use its Commercially Reasonable Effort to provide Manufacturing services to TG and Manufacture supply of LFB-R603 as required
for the Development and Commercialization of LFB-R603 when and as required by TG and shall take such actions as shall be reasonably
required to provide TG with supplies of LFB R603 for analytical development, non-clinical toxicology, pre-clinical activities and
clinical activities. *
and shall be pursuant to the Development Services and Manufacturing Agreement.

 

    	31

    	 

    

 

LICENSOR
shall provide a preliminary pharmaceutical development plan including major milestones and provisional budget within sixty (60)
days following the execution of the agreement, and a detailed pharmaceutical development plan, which shall be an appendix of the
Development Services and Manufacturing Agreement, within six (6) months following the execution of this Agreement.

 

(b)          Where
the cell culture Manufacturing capacity requested for Manufacturing and supply of LFB R603 for Clinical Trials is higher than *,
LICENSOR shall no longer have the exclusive right and responsibility to Manufacture directly or indirectly LFB R603 for Clinical
and Commercialization under. In this case, if LICENSOR is not appointed by TG for Manufacturing and supply of LFB R603, TG shall
pay to LICENSOR the extra-royalty under section 7.3.4

 

For the
sake of clarity, if LICENSOR provides, directly or indirectly, the supply of LFB R603 for Pivotal Clinical Trials, LICENSOR or
its Affiliates shall have the exclusive right and responsibility to provide Manufacturing services to TG and Manufacture and supply
LFB R603 as required for the Commercialization in the Territory. In such case the extra-royalty under Section 7.3.4 shall not apply

 

6.2           Supply
of TG20 for Development and Commercialization.

 

LICENSOR
and/ or its Affiliates shall have the exclusive right and responsibility to provide Manufacturing services to TG and Manufacture
supply of TG20. LICENSOR shall provide a preliminary pharmaceutical development plan including major milestones and provisional
budget within sixty (60) days following the execution of the agreement, and a detailed pharmaceutical development plan, which shall
be an appendix of the Development Services and Manufacturing Agreement, within six (6) months following the execution of this Agreement.
LICENSOR will be responsible for all aspects of manufacturing and facilities, including any additional capacity required at its
own expense and TG shall be responsible for Process Development (alone or with LICENSOR through the Development Services and Manufacturing
Agreement). Since LICENSOR and/or its Affiliates shall be a sole supplier of TG20 for the foreseeable future, LICENSOR shall use
its Commercially Reasonable effort to provide Manufacturing services to TG and Manufacture supply of TG20 as required for the Development
and Commercialization of TG 20 when and as required by TG and shall take such actions as shall be reasonably required to provide
TG with supplies of TG20 for analytical development, non-clinical toxicology, pre-clinical activities and clinical activities.
All supplies of Compound and Product for Clinical Trials supplied by LICENSOR shall be billed to TG at *.

 

 

*Confidential material redacted and filed separately
with the Commission.

 

    	32

    	 

    

 

Prior
to commencing Phase 3 Clinical Trials, parties will enter into a Commercial Supply Agreement, which shall be attached in Exhibit
B as soon as it is executed by the Parties and which shall include such customary terms of such agreements and shall include the
payment by TG to LICENSOR *
percent (*%). As part of such commercial supply agreement, LICENSOR and TG shall
establish the Joint Pharmaceutical, development and manufacturing Committee to serve as a forum for
information, coordination communication and forecasting of supply needs between the Parties with respect to the Manufacturing of
the Products by the LICENSORS and Commercialization by TG of the Compound and/or Products in
the Territory

 

6.3           Contractual
conditions for Process Development Services and supply of Compounds for Development.

 

For each Product, Process
Development Services and Supply of Compounds for Development shall be performed in accordance with the terms set forth in the Development
Services and Manufacturing Agreement.

 

7.          PAYMENTS

 

7.1           Issuance
of Equity. 

 

In consideration for
the rights granted to TG hereunder, TG hereby agrees to issue to LICENSOR, on the date hereof, the shares listed on Schedule8.,
on the terms and subject to the conditions set forth in the stock purchase agreement attached hereto as Exhibit C (the “Stock
Purchase Agreement”). Such Stock Purchase Agreement contains a right of LICENSOR to appoint one (1) member to the Board
of Directors of TG.

 

7.2           Milestone
Payments.

 

7.2.1           Development
and Regulatory Milestones. TG shall make the following non-refundable, non-creditable payments to LICENSOR upon
the occurrence of each of the following milestone events for the first Product that achieves the corresponding milestone event
(unless otherwise provided below):

 

	 	 	Milestone Event	 	 	Milestone
 Payment	 
	1.	 	Completion of the first Phase 3 Clinical Trial for a Product	 	 	$*	 	
	2.	 	the earliest of the completion of the first Pivotal Clinical Trial and/or of the  second Phase 3 Clinical Trial for a Product	 	 	$*	 	
	3.	 	Acceptance of the first Drug Approval Application for a Product by the FDA	 	 	$*	 	
	4.	 	Receipt of the first Marketing Authorization for a Product by the FDA	 	 	$*	 	
	5.	 	Acceptance of the first Drug Approval Application for a Product by the EMA or the applicable Regulatory Authorities in any Major Market Country	 	 	$*	 	
	6.	 	Receipt of the first Marketing Authorization for a Product by the EMA or the applicable Regulatory Authorities in any Major Market Country	 	 	$*	 	
	 	 	 	 	 	 	 	 	 

 

 

*Confidential material redacted and filed separately
with the Commission.

 

    	33

    	 

    

 

 

7.2.2      Notice
and Payment of Milestones.

 

(a)          Notice
of Milestone Events. TG shall provide LICENSOR with prompt written notice upon the occurrence of each milestone event set forth
in Section 7.2.1. In the event that, notwithstanding the fact that TG has not given such a notice, LICENSOR believes any such milestone
event has occurred, it shall so notify TG in writing and shall provide to TG data, documentation or other information that supports
its belief.  Any dispute under this Section 7.2.2(a) that relates to whether or not a milestone event has occurred shall be
resolved in accordance with Section 14.1.

 

(b)          Single
Milestone Payments. TG shall make a milestone payment corresponding to each of the foregoing milestone events only once
under Section 7.2.1, regardless of (i) the number of Products that achieve such milestone event and (ii) the number of times such
milestone event occurs with respect to a Product. For the sake of clarity, each milestone event shall only trigger one milestone
payment.

 

7.3           Payment
of Royalties; Royalty Rates; Sublicense Royalties; Accounting and Records.

 

7.3.1      Payment
of Royalties.  Subject to the remainder of this Section 7.3, TG shall pay LICENSOR a non-refundable, non-creditable
royalty at royalty rate equal to * percent (*%)
of the Annual Net Sales of each Product in each Calendar Year (or partial Calendar Year) commencing with the First Commercial Sale
of such Product in any country in the Territory and ending upon the last day of the last Royalty Term for such Product in such
country. For purposes of clarity, Annual Net Sales shall be determined separately for each separate Product that is sold in a given
Calendar Year.

 

7.3.2      Sublicense
Royalties. Notwithstanding the foregoing, if TG sublicenses any of the Products in any country of the Territory, then in
such Territory for such Product, the TG shall pay to LICENSOR Sublicense Royalties in lieu of the royalties set forth above.

 

 

*Confidential material redacted and filed separately
with the Commission.

 

    	34

    	 

    

 

7.3.3       Adjustments
to Royalties for Generic Products. In the event that a Third Party sells a Generic Product (as defined below) in a country
in which a Product is then being sold and such Generic Product is not covered by a Valid Claim under the Licensed Patent Rights
or TG Program Patent Rights in such country, then during the period in which sales of the Generic Product by such Third Party are
equal to at least *
percent (*%) of TG’s volume-based market share of the Product in such country
(as measured by prescriptions or other similar information available in such country), the royalty rate applicable to Net Sales
of the Product in such country shall be reduced to * percent (*%). 
Notwithstanding the foregoing, TG’s right to reduce its royalty obligation under this Section 7.3.3(1) shall expire on the
first day of the Calendar Quarter immediately following the Calendar Quarter in which sales of such Generic Product account for
less than * percent (*%) of TG’s
volume-based market share of the Product in such country (as measured by prescriptions or other similar information available in
such country). For purposes of this Section 7.3.3), a “Generic Product” means a biosimilar product with
the same amino acid sequence as the Compound.

 

7.3.4       Adjustment
to Royalties and to Sublicense Royalties for loss of Manufacturing under section 6.2

 

In the event that LICENSOR loses its exclusive
right of Manufacturing under section 6.2 (b), TG shall pay to LICENSOR an additional royalty of: *
percent (*%) of Net Sales, *.

 

7.3.5       Payment
Dates and Reports.

 

(a)          Royalty
Payments. Royalty payments shall be made by TG with respect to each Product within thirty (30) days after the end of each Calendar
Quarter in which sales of such Product occur, commencing with the Calendar Quarter in which the First Commercial Sale of such Product
occurs. TG shall also provide, at the same time each such payment is made, a report showing: (a) the Net Sales of each Product
by type of Product and country in the Territory and, if applicable, by Combination Product; (b) the total amount of deductions
from gross sales to determine Net Sales; (c) the applicable royalty rate for Product in each country in the Territory after applying
any reductions set forth above; and (d) a calculation of the amount of royalty due to LICENSOR.

 

(b)          Sublicensee
Royalty. Sublicense Income Payments shall be made by TG to LICENSOR with respect to all Sublicense Income, within thirty (30)
days of the end of each Calendar Quarter in which such Sublicense Income is received by TG. TG shall also provide, at the same
time each such Sublicense Income is made, a report showing: (a) a detailed accounting of all Sublicense Income received during
the applicable Calendar Quarter; (a) the Net Sales of each Product by type of Product and country in each country covered by the
Sublicense Agreement; (b) the total amount of deductions from gross sales to determine Net Sales; (c) the amount of the royalty
payment that would be payable in such country based upon a royalty rate of * percent
(*%); and (d) a calculation of the aggregate *
payable to LICENSOR in U.S. Dollars. If no amounts are due to LICENSOR for a particular Calendar Quarter, the report
shall so state.

 

(c)          Royalties
on Licensed Trademarks. The above mentioned Royalty payments and Sublicense Royalties percentages includes a *
percent (*%) royalty in consideration of the grant of the license
to the Licensed Trademarks.

 

 

*Confidential material redacted and filed separately
with the Commission.

 

    	35

    	 

    

 

(d)          Payment
in Common Stock. In the event that on the date on which TG owes a milestone payment to LICENSOR pursuant to Section 7.2.1,
above, TG is publicly traded on a stock exchange then, subject to LICENSOR’s prior approval not to be unreasonably withheld,
such milestone payment may be made through the issuance of that number of shares of Common Stock of TG as shall equal the amount
of the milestone payment due and payable divided by the Average Closing Price. For purposes of this Section 7.3.5(c), the “Average
Closing Price” means the average of the closing prices of TG Common Stock on The NASDAQ Global Market (or, if Common
Stock of TG is not listed on the NASDAQ Global Market, the principal exchange or interdealer quotation system on which the TG Common
Stock is listed) for the thirty (30) trading days prior to the public announcement of the occurrence of the milestone event with
respect to which the milestone payment is being made, pursuant to the terms, and subject to the conditions, set forth in the Stock
Purchase Agreement.

 

7.3.6       Records;
Audit Rights. TG and its Affiliates, Sublicensees and Distributors shall keep and maintain for three (3) years from
the date of each payment of royalties and/or Sublicense Royalties hereunder complete and accurate records of gross sales and Net
Sales by TG and its Affiliates, Sublicensees and Distributors of each Product, in sufficient detail to allow royalties and/or
Sublicense Royalties to be accurately determined. LICENSOR shall have the right for a period of three (3) years after receiving
any such royalty payment to appoint at its expense an independent certified public accountant reasonably acceptable to TG to
audit the relevant records of TG and its Affiliates, Sublicensees and Distributors to verify that the amount of each such
payment was correctly determined; provided, that, (a) if requested by TG, LICENSOR shall cause the independent certified public
accountant to enter into a confidentiality agreement reasonably acceptable to TG and (b) such independent certified public accountant
may only disclose to LICENSOR whether the royalties and/or Sublicense Royalties paid are correct and the details with respect to
any discrepancies. TG and its Affiliates, Sublicensees and Distributors shall each make its records available for audit
by such independent certified public accountant during regular business hours at such place or places where such records are customarily
kept, upon thirty (30) days written notice from LICENSOR. Such audit right shall not be exercised by LICENSOR more than once in
any Calendar Year or more than once with respect to sales of a particular Product in a particular period. All records made available
for audit shall be deemed to be Confidential Information of TG. The results of each audit, if any, shall be binding on both Parties
absent manifest error. In the event there was an underpayment of royalties by TG hereunder, TG shall promptly (but
in any event no later than thirty (30) days after TG’s receipt of the report so concluding) make payment to LICENSOR of any
shortfall. LICENSOR shall bear the full cost of such audit unless such audit discloses an underpayment by TG of five percent (5%)
or more of the aggregate amount of royalties and/or Sublicense Royalties payable in any Calendar Year, in which case TG
shall reimburse LICENSOR for all costs incurred by LICENSOR in connection with such audit.

 

7.3.7       Overdue
Payments. All royalty payments not made within the time period set forth in Section 7.3.5, and all milestone payments not
made within the time period specified in Section 7.2.1, shall bear interest at the rate of *
percent (*%) * until paid in full
or, if less, the maximum interest rate permitted by Applicable Laws. Any such overdue royalty or milestone payment shall, when
made, be accompanied by, and credited first to, all interest so accrued.

 

 

*Confidential material redacted and filed separately
with the Commission.

 

    	36

    	 

    

 

7.3.8       Payments;
Withholding Tax; Currency Restrictions.

 

(a)          Payments
in United States Dollars. Except as set forth in Section 6.3.7(b) below, all payments made by TG under this Article 6 shall
be made by wire transfer in United States Dollars in accordance with wire transfer instructions provided to TG in writing from
time to time by LICENSOR. If in any Calendar Quarter, Net Sales are made in any currency other than United States Dollars, such
Net Sales shall be converted into United States Dollars as follows:

 

(A/B), where

 

A = foreign “Net Sales”
(as defined above) in such Calendar Quarter expressed in such foreign currency; and

 

B = foreign exchange conversion
rate, expressed in local currency of the foreign country per United States Dollar (using, as the applicable foreign exchange rate,
the spot purchase rate published in the Financial Times on the last Business Day of each Calendar Quarter in which any payment
is due and payable or any other mutually agreed upon source, for such Calendar Quarter).

 

(b)          Tax
Withholding. If Applicable Laws require withholding of income or other taxes imposed upon any payments made by TG to LICENSOR
under this Agreement, TG shall (i) make such withholding payments as may be required, (ii) subtract such withholding payments from
such payments to be made to LICENSOR, (iii) submit appropriate proof of payment of the withholding taxes to LICENSOR within a reasonable
period of time, and (iv) promptly provide LICENSOR with all official receipts with respect thereto.

 

(c)          Currency
Restrictions. If any restrictions on the transfer of currency exist in any country in which Products are sold that prevent
TG from making royalty payments thereon in United States Dollars, TG shall make royalty payments on the sales in such country in
the local currency by deposit in a local bank or other depository designated in writing by LICENSOR (or, in the absence of such
designation, at a local bank or other depository selected by TG and identified by TG by written notice to LICENSOR).

 

8.          TREATMENT
OF CONFIDENTIAL INFORMATION; PUBLICITY

 

8.1     
   Confidentiality.

 

8.1.1           Confidentiality
Obligations. LICENSOR and TG each recognize that the other Party’s Confidential Information and Proprietary Materials
constitute highly valuable assets of such other Party. LICENSOR and TG each agrees that, (a) subject to Section 8.1.2, during the
Term and for an additional ten (10) years after termination or expiration of this Agreement it will not disclose, and will cause
its Affiliates, Sublicensees (with respect to TG) and Distributors or Sublicensees (with respect to LICENSOR) not to disclose whether
directly or indirectly, in any manner whatsoever, any Confidential Information or Proprietary Materials of the other Party and
(b) it will not use, and will cause its Affiliates, Sublicensees (with respect to TG) and Distributors or Sublicensees (with respect
to LICENSOR) not to use, any Confidential Information or Proprietary Materials of the other Party, without the prior written consent
of the Disclosing Party, except as expressly permitted hereunder.

 

    	37

    	 

    

 

8.1.2           Limited
Disclosure. LICENSOR and TG each agrees that disclosure of its Confidential Information or any transfer of its Proprietary
Materials may be made by the other Party on a need-to-know basis to any employee, consultant or Affiliate of such other Party or,
to the extent the other Party is TG, to any Third Party subcontractor engaged by TG pursuant to Section 2.2, in each case solely
to the extent reasonably necessary to enable such other Party to exercise its rights or to carry out its responsibilities under
this Agreement; provided, that, any such disclosure or transfer shall only be made to Persons who are bound by written obligations
comparable in scope to the obligations described in Section 8.1.3. LICENSOR and TG each further agrees that the other Party may
disclose its Confidential Information (a) on a need-to-know basis to such other Party’s legal and financial advisors, (b)
as reasonably necessary in connection with an actual or potential (i) permitted sublicense of such Party’s rights hereunder,
(ii) debt or equity financing of such other Party or (iii) acquisition, consolidation, share exchange or other similar transaction
involving such Party and any Third Party, (c) to the extent the other Party is TG, to any Third Party that is or may be engaged
by TG to perform services in connection with the Commercialization of Products as necessary to enable such Third Party to perform
such services, (d) as reasonably necessary to make Regulatory Filings with respect to Products under this Agreement or to respond
to any inquiry made by any Regulatory Authority with respect to Products and to prosecute or maintain Patent Rights, or to file,
prosecute or defend litigation related to Patent Rights, in accordance with this Agreement; (e) as required by Applicable Laws
(which shall be determined by the Disclosing Party in its reasonable discretion); provided, that, in the case of any disclosure
under this clause (e), the Disclosing Party shall (i) if practicable, provide the other Party with reasonable advance notice of
and an opportunity to comment on any such required disclosure and (ii) if requested by the other Party, cooperate in all reasonable
respects with the other Party’s efforts to obtain confidential treatment or a protective order with respect to any such disclosure,
at the other Party’s expense.

 

8.1.3           Employees
and Consultants. LICENSOR and TG each hereby covenants and agrees that all of its employees and consultants, and all of
the employees and consultants of its Affiliates, who have access to Confidential Information or Proprietary Materials of the other
Party will, prior to having such access, be bound by written obligations to maintain such Confidential Information or Proprietary
Materials in confidence that are no less stringent than those confidentiality and non-use provisions contained in this Agreement.
Each Party agrees to use, and to cause its Affiliates to use, reasonable efforts to enforce such obligations and to prohibit its
employees and consultants from using such information except as expressly permitted hereunder. Each Party will be liable to the
other Party for any disclosure or misuse by its employees of Confidential Information or Proprietary Materials of the other Party.

 

    	38

    	 

    

 

8.2           Publicity.

 

Notwithstanding anything
to the contrary in Section 8.1, the Parties, upon the execution of this Agreement, shall jointly issue a press release with
respect to this Agreement to be reasonably agreed by the Parties in substantially the form attached hereto as Schedule 6,
and either Party may make subsequent public disclosure of the contents of such press release without further approval of the other
Party. Subject to the foregoing, except as required by Applicable Laws (including those relating to disclosure of material information
to investors), neither Party shall issue a press or news release or make any similar public announcement (it being understood that
publication in scientific journals, presentation at scientific conferences and meetings and the like are intended to be covered
by Section 8.4 and not subject to this Section 8.2) related to the terms or existence of this Agreement or the conduct of the Development
Program or the Commercialization of Products without the prior written consent of the other Party; provided, however, that either
Party may make such a disclosure (a) to the extent required by Applicable Laws (including the requirements of any nationally recognized
securities exchange, quotation system or over-the-counter market on which such Party has its securities listed or traded), or (b)
to any investors, prospective investors, lenders and other potential financing sources who are obligated to keep such information
confidential. In the event that such disclosure is required as aforesaid, the disclosing Party shall make reasonable efforts to
provide the other Party with notice beforehand and to coordinate with the other Party with respect to the wording and timing of
any such disclosure. Once any press release or any other written statement is approved for disclosure by both Parties, either Party
may make subsequent public disclosure of the contents of such statement without the further approval of the other Party.

 

8.3           No
Use of Name.

Neither Party shall
use the name of the other Party in any Promotional Materials or advertising without the prior express written permission
of the other Party.

 

8.4           Publications
and Presentations.

Following the date
hereof, LICENSOR shall not publish or present any results (the “Results”) of the Development Program, without
the prior written consent of TG, such consent not to be unreasonably withheld.

 

9.          INTELLECTUAL
PROPERTY RIGHTS

 

9.1           LICENSOR
Intellectual Property Rights.

LICENSOR shall have
ownership of all right, title and interest, or license to, on a worldwide basis in and to any and all Licensed Technology and Licensed
Patent Rights.

 

9.2           Improvement

 

		9.2.1	TG agrees to notify LICENSOR of each Product Improvement TG, its Affiliates or its Sublicensees
has developed, conceived or acquired during the Term of this Agreement. TG shall, upon request of LICENSOR, provide to LICENSOR
all data and specifications concerning such Product Improvement. All Product Improvements shall be deemed to be considered as a
“Joint Improvement”.

  

    	39

    	 

    

 

		9.2.2	All LICENSOR Improvement shall be the exclusive and sole property of LICENSOR and shall become
Background Patent Right or Licensed Patent Rights, as the case may be.

 

9.3           Joint
Improvement

 

		9.3.1	Subject to any other provision to the contrary that may be contained in LICENSOR’s Licenses
as defined in Section 2.1.1, any Joint Improvement shall be jointly owned by TG and LICENSOR.

 

		9.3.2	TG shall have the exclusive, fully paid-up, irrevocable, transferable right to Use such Joint Improvements
in order to Develop the Compounds or Products as part of the Development Program and to Commercialize, use, have used, Manufacture,
have Manufactured, supply, sell, offer to sell, import, have imported, market, and otherwise Commercialize Products in the Field,
within the Territory with the right to sublicense .

 

		9.3.3	Each Party have the exclusive, fully paid-up, irrevocable, transferable right to Use such Joint
Improvements in order to develop and to commercialize have used, Manufacture, have Manufactured, supply, sell, offer to sell, import,
have imported, market, any product other than the Product and Compound.

 

		9.3.4	Each Party shall reasonably assist the other in preparing, prosecuting and maintaining Patent Rights
for Joint Improvements pursuant to section 9.4; 9.5 and 10.

  

9.4           Patent
Coordinators.

 

Each Party shall, by
written notice to the other Party, appoint a patent coordinator reasonably acceptable to the other Party (each, a “Patent
Coordinator”) to serve as such Party’s primary liaison with the other Party on matters relating to the filing, prosecution,
maintenance and enforcement of Patent Rights. Each Party may replace its Patent Coordinator at any time by notice in writing to
the other Party. The initial Patent Coordinators shall be:

 

	For LICENSOR:	Nicolas MARRO
	 	 
	For TG:	Lauren Friedberg

  

    	40

    	 

    

 

9.5           Notice;
Inventorship.

 

The Parties hereby
agrees to promptly notify to the other Party, through the Patent Coordinators, of the conception or reduction to practice of any
Program Technology or Joint-Improvement and to promptly execute any documents that may be necessary to perfect LICENSOR’s
rights in and to such Program Technology or Joint-Improvement. The Patent Coordinators shall determine inventorship of Program
Technology or Joint-Improvement under U.S. patent law. In case of a dispute between the Patent Coordinators over inventorship and,
as a result, whether any particular Technology is LICENSOR Technology or Joint Improvement,, such dispute shall be resolved according
to U.S. patent law by patent counsel selected by the Patent Coordinators who (and whose firm) is not at the time of the dispute,
and was not at any time during the five (5) years prior to such dispute, performing services for either of the Parties. Expenses
of such patent counsel shall be shared equally by the Parties.

 

10.         FILING,
PROSECUTION AND MAINTENANCE OF PATENT RIGHTS

 

10.1         Patent
Filing, Prosecution and Maintenance. 

 

10.1.1           LICENSOR
Prosecution Rights.  LICENSOR shall have the sole right and responsibility to prepare and file applications with
respect to, and prosecute and maintain, at its sole cost, expense and discretion, and using patent counsel or agents of its choice,
all Licensed Patent Rights (including all Joint Patent Rights that are Licensed Patent Rights) throughout the Territory. TG shall
cooperate with and assist LICENSOR in all reasonable respects, in connection with LICENSOR’s preparation, filing, prosecution
and maintenance of Licensed Patent Rights.

 

10.1.2           
TG Prosecution Rights. TG shall have the sole right and responsibility to prepare and file applications with respect to,
and prosecute and maintain, at its sole cost, expense and discretion, and using patent counsel or agents of its choice, all TG
Program Patent Rights throughout the Territory. LICENSOR shall cooperate with and assist TG in all reasonable respects, in connection
with TG’s preparation, filing, prosecution and maintenance of TG Program Patent Rights.

 

10.1.3           Joint
Patent Rights.  Subject to Section 10.1.1, within ten (10) Business Days after it is determined pursuant to Section 9.5
that any particular Program Technology is Joint Improvement, the Parties will determine which Party will undertake the prosecution
of such Joint Patent Rights based on the respective expertise of the Parties and the rights of the Parties under this Agreement.
If the Parties fail to agree within such ten (10) Business Day period, then prosecution of such Patent Rights shall be jointly
controlled by the Parties, using patent counsel agreed upon by the Patent Coordinators. All patent costs and expenses incurred
by a Party or jointly by the Parties in connection with the preparation, filing, prosecution and maintenance of Joint Patent Rights
in the Territory that cover any Product for use in the Field shall be shared equally by the Parties. Provided however that, if
a Party refuses, declines or fails to assume its obligations under this section 11.1.2, it shall advise the other Party and said
other Party shall have the right, at its own expense, to prepare, prosecute and maintain Patent Rights for Joint Improvements.
In such a case, upon request of the non-defaulting Party, the Party that refuses, declines or fails to file, prosecute or maintain
any such Patent Rights for Joint Improvements shall assign all its co-ownership rights to the other Party.

 

    	41

    	 

    

 

10.1.4    Information
and Cooperation. The Parties hereby agree to cooperate with each other in connection with the filing, prosecution and maintenance
of Patent Rights under this Agreement, including through the prompt execution and delivery of documents and instruments as may
reasonably be required in connection therewith. Without limiting the foregoing, each Party responsible for the filing, prosecution
and/or maintenance of Patent Rights under Sections 10.1.1 and/or 10.1.2 above (a “Filing Party”) shall (a) promptly
provide the other Party with copies of all patent applications filed hereunder and other material submissions and correspondence
with applicable patent offices, in sufficient time to allow for review and comment by the other Party; (b) provide the other Party
and its patent counsel with an opportunity to consult with the Party and its patent counsel regarding the filing and contents of
any such application, amendment, submission or response; and (c) take into consideration in good faith the advice and suggestions
of the other Party and its patent counsel in connection with such filing.

 

10.1.5    Interference,
Opposition, Reexamination and Reissue.

 

(a)          Notice.
Not more than thirty (30) days following the discovery by either Party of any request for, or the filing or declaration of, any
interference, opposition, or reexamination proceeding with respect to any Licensed Patent Rights in the Territory, the discovering
or determining Party shall notify the other Party of such event.

 

(b)          Primary
Responsibility and Cooperation. LICENSOR shall have primary responsibility, at its own expense, with respect to the course
of action taken to defend or prosecute any such interference, opposition, reexamination or reissue, except that the Parties shall
share equally the reasonable fees and expenses incurred under this Section 10.1.4(b) with respect to Joint Patent Rights. The Parties
shall cooperate fully with each other and each shall provide to the other any information or assistance that the other may reasonably
request with respect to any course of action taken under this Section 10.1.4. LICENSOR shall (a) keep TG reasonably informed of
all developments in such interference, opposition, reexamination or reissue in the Territory, including to the extent permissible,
the status of any settlement negotiations and the terms of any offer related thereto and (b) provide to TG copies of all submissions
or agreements arising in connection with such proceeding sufficiently in advance of their filing or due date so as to give TG sufficient
time to comment thereon, and LICENSOR shall give good faith consideration to TG’s comments, with due regard to the other
Party’s rights and commercial interests under this Agreement. Neither Party shall enter into any settlement or consent decree
regarding Joint Patent Rights, or assent to the grant of any reissued or reexamined patent within the Joint Patent Rights, without
the prior written consent of the other Party, which shall not be unreasonably withheld or delayed.

 

10.1.6   Decision
Not to File; Abandonment. LICENSOR shall notify TG in the event LICENSOR decides at any time to abandon or discontinue
prosecution of any one or more of the patents or patent applications included in the Licensed Patent Rights and in the Territory.
Such notification will be given as early as possible which in no event will be less than fifteen (15) days prior to the date on
which said patent(s) or patent application(s) will become abandoned. TG shall have the option, exercisable upon written notification
to LICENSOR, to assume full responsibility, at its discretion for the prosecution of the affected patent(s) or patent application(s),
which shall be conducted in the name of TG. 

 

    	42

    	 

    

 

10.2         Enforcement
and Defense.

 

10.2.1    Third
Party Infringement.

 

(a)          In
General.

 

(i)          Notice.
In the event either Party becomes aware of (i) any suspected infringement or misappropriation of any Licensed Patent Rights, Joint
Patent Rights that covers the development or commercialization of a Compound or Product in the Field in the Territory, or (ii)
the submission by any Third Party of an abbreviated NDA under the Hatch-Waxman Act for a product in the Field that comprises the
Compound (each, an “Infringement”), that Party shall promptly notify the other Party and provide it with all
details of such Infringement of which it is aware (each, an “Infringement Notice”). The Patent Coordinators
shall promptly meet to discuss the Infringement and the strategy for patent enforcement with respect to such Infringement.

 

(ii)         LICENSOR
Right to Enforce.  LICENSOR shall have the first right, but not the obligation, to address any such Infringement in
the Territory by taking reasonable steps, which may include the institution of legal proceedings or other actions (each, an “Action”),
and to compromise or settle such Action; provided, that, (A) LICENSOR shall keep TG reasonably informed about such Action, (B)
TG shall provide reasonable cooperation to LICENSOR in connection with such Action, (C) LICENSOR shall not take any position with
respect to, or compromise or settle, such Action in any way that would be reasonably likely to directly and adversely affect the
scope, validity or enforceability of the Licensed Patent Rights without the prior consent of TG, which consent shall not be unreasonably
withheld, and (D) if LICENSOR does not intend to prosecute or defend an Infringement, or determines to cease to pursue such an
Action, it shall promptly inform TG and Section 10.2.1(a)(iii) shall apply. LICENSOR shall incur no liability to
TG as a consequence of such Action or any unfavorable decision resulting therefrom, including any decision holding any such claim
invalid, not infringed or unenforceable.  All costs, including, without limitation, attorneys’ fees, relating to such
legal proceedings or other action shall be borne by LICENSOR.

 

(iii)        TG
Right to Enforce. If (A) LICENSOR informs TG that LICENSOR does not intend to prosecute an Action in respect of any Licensed
Patent Rights or Joint Patent Rights pursuant to Section 10.2.1(a)(ii), (B) within sixty (60) days after the Infringement Notice,
LICENSOR has not commenced any Action, or (C) if LICENSOR determine to cease to pursue any such Action with respect to such Infringement,
then TG shall have the right, at its own expense, upon notice to LICENSOR to take appropriate action to address such Infringement,
including by initiating its own Action or taking over prosecution of any Action initiated by LICENSOR; provided, that, in such
event, (1) TG shall keep LICENSOR reasonably informed about such Action and shall consult with LICENSOR before taking any major
steps during the conduct of such Action, (2) LICENSOR shall provide reasonable cooperation to TG in connection with such Action,
and (3) TG shall not take any position with respect to, or compromise or settle, such Action in any way that is reasonably likely
to directly and adversely affect the scope, validity or enforceability of the Licensed Patent Rights without LICENSOR’ prior
written consent, which consent shall not be unreasonably withheld. LICENSOR shall incur no liability to LICENSOR as a consequence
of such Action or any unfavorable decision resulting therefrom, including any decision holding any such claim invalid, not infringed
or unenforceable. All costs, including, without limitation, attorneys’ fees, relating to such legal proceedings or other
action shall be borne by TG.

 

    	43

    	 

    

 

(iv)        Joint
Patent Rights. In the event of an Infringement of a Joint Patent Right, the Parties shall enter into good faith discussions
as to whether and how to eliminate the Infringement. Subject to the foregoing, (A) TG shall have the first right and option to
eliminate such Infringement by reasonable steps, which may include the institution of legal proceedings or other action and (B)
all costs, including without limitation attorneys’ fees, relating to such legal proceedings or other action shall be borne
by TG. If TG does not take or initiate commercially reasonable steps to eliminate the Infringement within one hundred twenty (120)
days from any Infringement Notice (or twenty (20) days in the case of an Infringement resulting from the submission by any Third
Party of an abbreviated new drug application under the Hatch-Waxman Act), then LICENSOR shall have the right an option to do so
at its expense.

 

(b)         Right
to Representation. Each Party shall have the right to participate and be represented by counsel that it selects, in any Action
instituted under Section 10.2.1(a)(ii), (iii) or (iv) by the other Party. If a Party with the right to initiate an Action under
Section 10.2.1(a) to eliminate an Infringement lacks standing to do so and the other Party has standing to initiate such Action,
then the Party with the right to initiate an Action under Section 10.2.1(a) may name the other Party as plaintiff in such Action
or may require the Party with standing to initiate such Action at the expense of the other Party.

 

(c)         Cooperation.
In any Action instituted under this Section 10.2.1, the Parties shall cooperate with and assist each other in all reasonable respects.
Upon the reasonable request of the Party instituting such Action, the other Party shall join such Action and shall be represented
using counsel of its own choice, at the requesting Party’s expense.

 

(d)         Allocation
of Proceeds. Any amounts recovered by either Party pursuant to Actions under Sections 10.2.1(a)(ii), (iii) or (iv) with respect
to any Infringement, whether by settlement or judgment, shall, after reimbursing TG and LICENSOR for their respective reasonable
out-of-pocket expenses incurred in pursuing such Action and obtaining such recovery (which amounts shall be allocated pro rata
if insufficient to cover the totality of such expenses) be retained by or paid to TG and treated as Net Sales of the Product affected
by the Infringement for purposes of this Agreement, such that TG shall pay to LICENSOR the applicable royalty due on such Net Sales
pursuant to Section 7.3.1.

 

10.2.2     Defense
of Claims.

 

(a)          Notice.
In the event that any action, suit or proceeding is brought against either Party or any Affiliate of either Party or any Sublicensee
or Distributor of TG alleging the infringement of the Technology or Patent Rights of a Third Party by reason of or the Development
or Commercialization, including the Manufacture, use or sale, of any Compound or Product, by or on behalf of TG, its Affiliates,
Sublicensees or Distributors, such Party shall notify the other Party within five (5) days of the earlier of (i) receipt of service
of process in such action, suit or proceeding, or (ii) the date such Party becomes aware that such action, suit or proceeding has
been instituted and the Patent Coordinators shall meet as soon as possible to discuss the overall strategy for defense of such
matter.

 

    	44

    	 

    

 

(b)          Prosecution
of Infringement claims in the Territory. Except as unanimously agreed by the Patent Coordinators and subject to Article
14, (i) LICENSOR shall have the primary right but not the obligation to institute and control such action, suit or proceeding in
its own name and at its sole expense and in such case, LICENSOR and/or any of its Affiliates shall have the right to separate counsel
at its own expense in any such action, suit or proceeding and, TG shall cooperate with LICENSOR in all reasonable respects in any
such action, suit or proceeding ; (ii) in the event LICENSOR waives its primary right as defined in (i) the Parties may elect,
without being obliged, to jointly commence an action, an in this respect shall be represented by a counsel jointly chosen by the
Parties, decide on a course of action, and share equally in the costs and expenses, and in the amounts recovered in accordance
with, subject to and within the limits set out in LICENSOR’s Licenses or (iii) Upon LICENSOR’s request TG may defend
any action, suit or proceeding in its own name and at its sole expense and in such case TG and/or any of its Affiliates shall have
the right to separate counsel at its own expense in any such action, suit or proceeding and LICENSOR shall cooperate with TG in
all reasonable respects in any such action, suit or proceeding .

 

(c)          Cooperation.
Each Party shall promptly furnish the other Party with a copy of each communication relating to the alleged infringement that is
received by such Party including all documents filed in any litigation. In no event shall either Party settle or otherwise resolve
any such action, suit or proceeding brought against the other Party or any of its Affiliates or sublicensees without the other
Party’s prior written consent.

 

10.2.3    Patent
Term Restoration. The Parties hereto shall cooperate with each other in obtaining patent term restoration or supplemental
protection certificates or their equivalents in any country in the Territory where applicable to Licensed Patent Rights. Such cooperation
shall include diligently and timely conferring and coordinating with respect to such matters to ensure compliance with applicable
filing deadlines, and agreeing on procedures to be followed by the Parties to ensure such compliance. In the event that elections
with respect to obtaining such patent term restoration are to be made, LICENSOR shall have the right to make the election with
respect to Licensed Patent Rights.

 

10.3         Trademark
Prosecution and Registration.

 

LICENSOR shall control
the registration of the Licensed Trademark, to be used with Products in the Territory. LICENSOR shall have the primary right and
obligation to take any actions as are required to continue and maintain in full force and effect and enforce and defend all Licensed
Trademarks and registrations thereof, against infringement and misappropriation in the Territory, and shall be solely responsible
for all expenses incurred in connection therewith. Upon LICENSOR’s request TG may have the right to take any actions as are
required to continue and maintain in full force and effect and enforce and defend all Licensed Trademarks and registrations thereof,
against infringement and misappropriation in the Territory, and shall be solely responsible for all expenses incurred in connection
therewith.

 

    	45

    	 

    

 

11.         TERM
AND TERMINATION

 

11.1         Term.

 

This Agreement shall
commence on the Effective Date and shall continue in full force and effect, unless otherwise terminated pursuant to Section 11.2,
(a) until such time as TG is no longer Developing at least one (1) Compound and/or at least one (1) Product or (b) if, as of the
time TG is no longer Developing at least one (1) Compound and/or at least one (1) Product, TG is Commercializing a Product, until
the later of (i) the expiration of all applicable Royalty Terms with respect to Products and (ii) the expiration of all obligations
of TG to pay Sublicense Royalties to LICENSOR under this Agreement (the “Term”). Upon the expiration of this Agreement
as set forth in this Section 11.1, the license rights granted hereunder shall be converted to perpetual and fully paid-up licenses
on Licensed Technology and Licensed Patent Rights, with the right to grant unlimited sublicenses. However, TG shall continue
to pay to LICENSOR royalties on the use of Licensed Trademarks as defined in section 7.3.4. c.).

 

11.2         Termination.

 

This Agreement may
be terminated by either Party as follows:

 

11.2.1     Unilateral
Right to Terminate Agreement.

 

(a)          LICENSOR
Rights to Terminate for Challenge.  Except to the extent the following is unenforceable under the Applicable Laws of a
particular jurisdiction where a patent application within the Licensed Patent Rights is pending or a patent within the Licensed
Patent Rights is issued, LICENSOR may terminate this Agreement immediately upon written notice to TG in the event that TG or any
of its Affiliates or Sublicenses Challenges any Licensed Patent Rights or assists a Third Party in initiating a Challenge of any
Licensed Patent Rights.

 

11.2.2     Termination
for Breach. Either Party may terminate this Agreement, effective immediately upon written notice to the other Party, for
a material breach (including TG’s failure to meet its diligence requirements and responsibilities as set forth in Section
3; 4 and 5) by the other Party of any term of this Agreement that remains uncured ninety (90) days (sixty (60) days in the event
that the breach is a failure of a Party to make any payment required hereunder) after the non-breaching Party first gives written
notice to the other Party of such breach and its intent to terminate this Agreement if such breach is not cured. For purposes of
clarity, the obligation of the breaching Party to cure any such breach shall be stayed for any time period during which such breach
is the subject of a dispute resolution proceeding pursuant to Section 14.1; provided, that, the obligation of the breaching Party
to cure such breach such breach shall resume commencing on the date of any final resolution of such proceeding.

 

11.2.3     Termination
for Insolvency. In the event that either Party makes an assignment for the benefit of creditors, appoints or suffers appointment
of a receiver or trustee over all or substantially all of its property, files a petition under any bankruptcy or insolvency act
or has any such petition filed against it which is not discharged within sixty (60) days of the filing thereof, then the other
Party may terminate this Agreement effective immediately upon written notice to such Party.

 

11.3         Consequences
of Termination of Agreement.

 

In the event of the
termination of this Agreement pursuant to Section 11.2, the following provisions shall apply, as applicable.

 

    	46

    	 

    

 

 

11.3.1    Termination
by LICENSOR. If this Agreement is terminated by LICENSOR pursuant to Section 11.2.1, 11.2.2 or 11.2.3:

 

(a)          All
licenses and rights granted by LICENSOR to TG, including all licenses granted to TG pursuant to Section 2.1, shall immediately
terminate.

 

(b)          TG
shall cease to use any and all Licensed Trademarks, any Marketing Authorization obtained in accordance with the AGREEMENT and shall
further promptly transfer such Marketing Authorizations and/or orphan drug designations to LICENSOR at no cost for LICENSOR.

 

(c)          TG
shall cease to conduct any activity related to the Development and Commercialization of the Product.

 

(d)          Upon
request of LICENSOR, TG shall promptly, and in any event within sixty (90) days after LICENSOR’s request (which request may
specify any or all of the actions in clauses (A) through (H): (A) transfer to LICENSOR all of its right, title and interest in
all Drug Approval Applications and then in its name applicable to the Product, if any, and all Confidential Information Controlled
by TG as of the date of termination relied on by such Drug Approval Applications; (B) notify the applicable Regulatory Authorities
and take any other action reasonably necessary to effect such transfer; (C) provide LICENSOR with copies all correspondence between
TG and such Regulatory Authorities relating to such Drug Approval Applications; (D) unless expressly prohibited by any Regulatory
Authority, transfer sponsorship and control to LICENSOR of all Clinical Trials of the Product being conducted as of the effective
date of termination and continue to conduct such Clinical Trials after the effective date of termination to enable such transfer
to be completed without interruption of any such Clinical Trial for up to twelve (12) months from the effective date of termination,
except for termination for breach of TG, the fully burdened cost of such continuation to be paid for by LICENSOR (E) cooperate
with LICENSOR, cause its Affiliates to cooperate with LICENSOR and use commercially reasonable efforts to require any Third Party
with which TG has an agreement with respect to the conduct of Clinical Trials for the Product (including agreements with contract
research organizations, clinical sites and investigators), to cooperate with LICENSOR in order to accomplish the transfer to LICENSOR
of similar rights as held by TG under its agreements with such Third Parties; (F) provide LICENSOR with copies of all reports and
Clinical Data generated or obtained by TG or its Affiliates, and all Promotional Materials used by TG, pursuant to this Agreement
that relate to the Product that have not previously been provided to LICENSOR and provide LICENSOR with a right of access, a right
of reference and a right to use and incorporate all Clinical Data, results and information in all Drug Approval Applications then
in its name applicable to the commercialization of Product and all material aspects of Confidential Information Controlled by it
as of the date relating to such Drug Approval Applications for LICENSOR to use to seek Regulatory Approvals; (G) provide LICENSOR
at cost with all supplies of Compounds an Products in the possession of TG or any Affiliate or contractor of TG; and (H) provide
LICENSOR with copies of all reports and data generated or obtained by TG or its Affiliates pursuant to this Agreement that relate
to any Product that have not previously been provided to LICENSOR; (I) enter into negotiations with LICENSOR and agree upon and
implement a plan for the orderly transition of Development and Commercialization from TG to LICENSOR in a manner consistent with
Applicable Laws and standards of ethical conduct of human Clinical Trials and will seek to replace all TG personnel engaged in
any Development or Commercialization activities, in each case, as promptly as practicable. In connection therewith, TG shall be
deemed to have granted to LICENSOR an exclusive, fully-paid, royalty-free, irrevocable license, with the right to grant sublicenses
under TG’s interest in Joint Improvements and Joint Patent Rights, for the sole purpose of using, making, having made, offering
for sale, selling, having sold, importing and exporting any Products being Developed and/or Commercialized by TG as of the effective
date of such termination in the Field and in the Territory.

 

    	47

    	 

    

 

(e)          Each
Party shall promptly return all Confidential Information and Proprietary Materials of the other Party that are not subject to a
continuing license hereunder; provided, that, each Party may retain one copy of the Confidential Information of the other Party
in its archives solely for the purpose of establishing the contents thereof and ensuring compliance with its obligations hereunder.

 

(f)          TG
shall promptly return to LICENSOR all raw data and results generated in each such Clinical Trial

 

11.3.2    Termination
by TG. If this Agreement is terminated by TG pursuant to Section, 11.2.2 or 11.2.3:

 

(a)          At
TG’s election, all licenses granted by LICENSOR to TG pursuant to Section 2.1 shall survive such termination, in each case
subject to TG’s continued payment of all milestone, royalty, Sublicense Royalties and other payments under and in accordance
with this Agreement with respect thereto.

 

(b)          Each
Party shall promptly return all Confidential Information and Proprietary Materials of the other Party that are not subject to a
continuing license hereunder; provided, that, each Party may retain one copy of the Confidential Information of the other Party
in its archives solely for the purpose of establishing the contents thereof and ensuring compliance with its obligations hereunder.

 

(c)          TG
shall promptly return to LICENSOR all raw data and results generated in each such Clinical Trial

 

11.4       Surviving
Provisions.

 

Termination or expiration
of this Agreement for any reason shall be without prejudice to:

 

(a)          Survival
of rights specifically stated in this Agreement to survive, including without limitation as set forth in Section 11.3;

 

(b)          the
rights and obligations of the Parties provided in Sections 8, 9, 10, 12, 13, 14.1 and 14.2 (including all other Sections or Articles
referenced in any such Section or Article), all of which shall survive such termination except as provided in this Article 10;
and

 

(c)          any
other rights or remedies provided at law or equity which either Party may otherwise have.

 

    	48

    	 

    

  

12.     REPRESENTATIONS
AND WARRANTIES 

 

12.1       Mutual
Representations and Warranties. 

 

LICENSOR and TG
each hereby represents and warrants to the other, as of the Effective Date, as follows:

 

12.1.1           Organization.
It is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization,
and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement.

 

12.1.2           Authorization.
The execution and delivery of this Agreement and the performance by it of the transactions contemplated hereby have been duly authorized
by all necessary corporate action and will not violate (a) such Party’s certificate of incorporation or bylaws (or equivalent
charter or organizational documents), (b) any agreement, instrument or contractual obligation to which such Party is bound in any
material respect, (c) any requirement of any Applicable Laws, or (d) any order, writ, judgment, injunction, decree, determination
or award of any court or governmental agency presently in effect applicable to such Party.

 

12.1.3           Binding
Agreement. This Agreement is a legal, valid and binding obligation of such Party enforceable against it in accordance with
its terms and conditions.

 

12.1.4           No
Inconsistent Obligation. It is not under any obligation, contractual or otherwise, to any Person that conflicts with or
is inconsistent in any respect with the terms of this Agreement or that would impede the diligent and complete fulfillment of its
obligations hereunder.

 

12.1.5           No
Government Authorization Required. No government authorization, consent, approval, license, exemption of or filing or registration
with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any
Applicable Laws currently in effect, is or will be necessary for, or in connection with, the transactions contemplated by this
Agreement, or for the performance by it of its obligations under this Agreement.

 

12.1.6           TG
represents and warrants that it has all necessary financial and human resources to enter and perform all its commitments and obligations
contained in the Agreement.

 

12.2       Additional
Representations of LICENSOR.

 

LICENSOR further represents
and warrants to TG, as of the Effective Date, as follows:

 

12.2.1           Validity
of Patent Rights. All Licensed Patent Rights listed on Schedule 4 are existing and, to LICENSOR’ Knowledge,
no issued patents which are part of the Licensed Patent Rights listed on Schedule 4 are invalid or unenforceable.

 

    	49

    	 

    

 

12.2.2           No
Claims.  There are no claims, judgments or settlements against LICENSOR pending, or to LICENSOR’ Knowledge,
threatened, that invalidate or seek to invalidate the Licensed Patent Rights. There is no litigation pending against LICENSOR or
any Affiliate of LICENSOR that alleges that any of LICENSOR’ activities relating to the Compound have violated, or by Developing
the Compound would violate, any of the intellectual property rights of any Third Party (nor has it received any written communication
threatening such litigation). To LICENSOR’ Knowledge, no litigation has been threatened against LICENSOR or any Affiliate
of LICENSOR which alleges that any of its activities relating to the Compound have violated, or by Developing the Compound would
violate, any of the intellectual property rights of any Third Party.

 

12.2.3           No
License. LICENSOR has not previously entered into any agreement pursuant to which it granted a license with respect to
the Compound, or Product or under the Licensed Patent Rights or Licensed Technology to any Affiliate or Third Party, which license
grant remains in effect or which agreement has surviving license rights, or other surviving terms, that are inconsistent with the
rights and licenses granted to TG under this Agreement.

 

12.2.4           Third
Party Patents.  Except the patents disclosed in the dataroom and to LICENSOR’ Knowledge, no Patent Rights
owned or controlled by any Third Party would be infringed by the Development, Manufacture, use of Commercialization by or on behalf
of TG of the Compound or any Product pursuant to this Agreement.

 

12.2.5           No
Interference. To LICENSOR’ Knowledge, (a) the Licensed Patent Rights are not the subject of any interference proceeding
and (b) there is no pending or threatened action, suit, proceeding or claim by any Third Party challenging LICENSOR’ ownership
rights in, or the validity or scope of, the Licensed Patent Rights.

 

12.3       Additional
Representations of TG.

 

TG further represents
and warrants to LICENSOR, as of the Effective Date, as follows:

 

12.3.1           No
Claims.  There is no litigation pending against TG or any Affiliate of TG that relates, directly or indirectly,
to the subject matter of this Agreement and that alleges that any of TG’s activities to be conducted relating to the Development
of the Compound would violate any of the intellectual property rights of any Third Party (nor has it received any written communication
threatening such litigation).

 

12.3.2           Compliance
with Applicable Laws.  TG is in compliance with all Applicable Laws, and is not in default under or in violation
of any Applicable Laws, that, in any case, would reasonably be expected to adversely affect the ability of TG to comply with and
perform its obligations under this Agreement.

 

12.3.3           Electronic
Dataroom. TG represents and warrants that it has been granted access to an electronic dataroom organized by LICENSOR and
therefore has a clear and perfect knowledge and a good understanding of all documents, information and data contained in such electronic
dataroom, and their consequences on rights granted by LICENCOR under the Agreement. Within thirty (30) days of the date hereof,
LICENSOR will use Commercially Reasonable Efforts to transfer a copy of the contents of the electronic dataroom in their original
format to TG and will transfer such other manifestations of the Licensed Technology useful or necessary for TG to Develop and Commercialize
the Products, including without limitation raw data and results generated in each clinical trial and pre-clinical studies 
previously conducted and batch reports from manufacturing runs through the date hereof, to the extent not included in the dataroom. 
On and after the date hereof, LICENSOR will use Commercially Reasonable Efforts to forward such manifestations of the Licensed
Technology that it has in its possession to TG on a regular basis or upon request.

 

    	50

    	 

    

 

 

13.         INDEMNIFICATION;
INSURANCE

 

13.1         Indemnification
of LICENSOR by TG.

 

TG shall indemnify,
defend and hold harmless LICENSOR, its Affiliates, their respective directors, officers, employees and agents, and their respective
successors, heirs and assigns (collectively, the “LICENSOR Indemnities”), against all liabilities, damages,
losses and expenses (including, without limitation, reasonable attorneys’ fees and expenses of litigation) (collectively,
“Losses”) incurred by or imposed upon LICENSOR Indemnities, or any of them, as a direct result of claims, suits,
actions, demands or judgments of Third Parties, including, without limitation, personal injury and product liability claims (collectively,
“Claims”), arising out of (a) the Development, testing, sale, offer for sale, or Commercialization by TG or
any of its Affiliates, Sublicensees or Distributors of any Product; (b) any breach of this Agreement by TG or any of its Affiliates,
Sublicensees, Distributors or agents; and (c) the gross negligence or willful misconduct of any TG Indemnity or Sublicensee of
TG; excluding, in each of (a), (b) and (c) above, any Claim or Loss with respect to which LICENSOR has an obligation to indemnify
TG Indemnities pursuant to Section 13.2, as to which Claim or Loss each Party will indemnify the other to the extent of their respective
liability for such Loss (unless such Claim or Loss is otherwise expressly excluded from a Party’s indemnification obligations
under this Agreement).

 

13.2         Indemnification
of TG by LICENSOR.

 

LICENSOR shall indemnify,
defend and hold harmless TG, its Affiliates, their respective directors, officers, employees and agents, and their respective successors,
heirs and assigns (collectively, the “TG Indemnities”), against all Losses incurred by or imposed upon the TG
Indemnities, or any of them, as a direct result of Claims arising out of (a) the commercialization by LICENSOR of any LICENSOR
Commercialization Product in the LICENSOR Commercialization Territory following exercise of LICENSOR commercialization option (b)
any breach of this Agreement by LICENSOR or any of its Affiliates, (sub)licensees, distributors or agents; or (b) the gross
negligence or willful misconduct of any LICENSOR Indemnity or (sub)licensee of LICENSOR; excluding, in the case of clauses (a)
and (b) above, any Claim or Loss with respect to which TG or any of its Affiliates has an obligation to indemnify LICENSOR pursuant
to Section 13.1, as to which Claim or Loss each Party will indemnify the other to the extent of their respective liability for
such Loss.

 

    	51

    	 

    

 

13.3         Conditions
to Indemnification.

 

A Person seeking modification
under this Article 13 (the “Indemnified Party”) in respect of a Claim shall give prompt notice of such Claim
to the Party from which indemnification is sought (the “Indemnifying Party”); provided, that, the Indemnifying
Party is not contesting its obligation under this Section 13, shall permit the Indemnifying Party to control any litigation relating
to such Claim and the disposition of such Claim; provided, that, the Indemnifying Party shall (a) act reasonably and in good faith
with respect to all matters relating to the settlement or disposition of such Claim as the settlement or disposition relates to
such Indemnified Party and (b) not settle or otherwise resolve such claim without the prior written consent of such Indemnified
Party (which consent shall not be unreasonably withheld, conditioned or delayed). Each Indemnified Party shall cooperate with the
Indemnifying Party in its defense of any such Claim in all reasonable respects and shall have the right to be present in person
or through counsel at all legal proceedings with respect to such Claim.

 

13.4         Insurance.

 

Not later than thirty
(30) days before the date on which TG or any Affiliate or Sublicensee of TG shall, on a commercial basis, make, use, or sell any
Products, and at all times thereafter until the expiration of all applicable statutes of limitation pertaining to any such manufacture,
marketing, possession, use, sale of other disposition of any Products, TG will, at its expense, and LICENSOR will, at its expense,
with respect to Products, obtain and maintain in full force and effect, comprehensive general liability insurance, including product
liability insurance and Clinical Trial insurance in such amounts as each such Party customarily maintains with respect to the development,
manufacture and sale of its other products. Notwithstanding the foregoing, either Party may elect to self-insure with respect to
any insurance coverage it is required to obtain hereunder as part of a comprehensive self-insurance program adopted by such Party.
For the avoidance of doubt, all insurance obligations and associated costs for any sale and development of Product within the Territory
and over which LICENSOR has little or no control, shall be borne solely by TG.

 

13.5         Warranty
Disclaimer.

 

EXCEPT AS OTHERWISE
EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY KNOW-HOW, GOODS, SERVICES, RIGHTS OR
OTHER SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION,
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT.

 

13.6         No
Warranty of Success.

 

Nothing contained in
this Agreement shall be construed as a warranty, either express or implied, on the part of either Party that (a) the Development
Program will yield a Product or otherwise be successful or meet its goals, time lines or budgets, or (b) the outcome of the Development
Program will be commercially exploitable in any respect.

 

13.7         Limited
Liability.

 

EXCEPT AS SET FORTH
UNDER SECTIONS 13.1 OR 13.2, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR (I) ANY SPECIAL, PUNITIVE,
INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING, WITHOUT LIMITATION, LOST PROFITS OR LOST REVENUES, OR (II) COST OF PROCUREMENT
OF SUBSTITUTE GOODS, KNOW-HOW OR SERVICES, WHETHER UNDER ANY CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR
EQUITABLE THEORY.

 

    	52

    	 

    

 

14.    MISCELLANEOUS

 

14.1         Disputes;
Consent to Jurisdiction.  

 

The Parties shall use
reasonable efforts to settle any Disputed Matter arising from or related to this Agreement or the breach thereof (each, a “Dispute”)
by promptly referring any such dispute to the Executive Officer of each Party. If the Executive Officers are unable to resolve
any Dispute within thirty (30) days of the date on which the Dispute was referred to them for resolution, the Dispute shall be
subject to the sole jurisdiction of, and venue in, the U.S. federal courts of competent jurisdiction located within Boston, Massachusetts,
USA (if available), and otherwise the state courts of competent jurisdiction located within Boston, Massachusetts, USA. TG and
LICENSOR each irrevocably consent to the jurisdiction of such courts, irrevocably waive any objection based on inconvenience of
forum, and agree that process may be served in the manner provided herein for giving notices or otherwise as allowed by Massachusetts
or applicable federal law. Notwithstanding the foregoing, either Party shall have the right, without waiving any right or remedy
available to such Party under this Agreement or otherwise, to seek and obtain from any court of competent jurisdiction any interim
or provisional relief that is necessary or desirable to protect the rights or property of such Party.

 

14.2         Notices.

 

All notices and communications
shall be in writing and delivered personally or by internationally-recognized overnight express courier providing evidence of
delivery or mailed via certified mail, return receipt requested, addressed as follows, or to such other address as may be designated
from time to time:

 

		If to LICENSOR:	GTC Biotherapeutics, Inc.

175 Crossing Boulevard

Framingham, MA
01701

Attention: _______________

Tel.: 508-620-9700

Fax: ___________________

 

LFB Biotechnologies S.A.S.

3 avenue des Tropiques

B.P. 305-Les Ulis- 91958

Courtaboeuf Cedex, France

Attention: _______________

Tel.: ____________________

Fax: ____________________

 

    	53

    	 

    

 

LFB/GTC LLC

175 Crossing Boulevard

Framingham, Massachusetts
01701

Attention: ________________

Tel. ______________________

Fax: ______________________

 

With a copy to:

 

Mintz Levin Cohn Ferris Glovsky
and Popeo, P.C.

One Financial Center

Boston, MA 02111

Attention: Brian P. Keane, Esq.

Tel.: 617-542-6000

Fax: 617-542-2241

 

		If to TG:	TG Therapeutics, Inc.

787 Seventh Avenue

48th Floor

New York, NY 10019

Attn: __________________

Tel: ___________________

Fax: ___________________

 

With a copy to:

______________________

______________________

______________________

Attention: ______________

Tel: ___________________

Fax: __________________

 

Except as otherwise
expressly provided in this Agreement or mutually agreed in writing, any notice, communication or document (excluding payment) required
to be given or made shall be deemed given or made and effective upon actual receipt or, if earlier, (a) three (3) Business Days
after deposit with an internationally-recognized overnight express courier with charges prepaid, or (b) five (5) Business Days
after mailed by certified, registered or regular mail, postage prepaid, in each case addressed to a Parties at its address stated
above or to such other address as such Party may designate by written notice given in accordance with this Section 14.2.

 

14.3         Governing
Law.

 

This Agreement shall
be governed by and construed in accordance with the laws of the State of Delaware, without regard to the application of
principles of conflicts of law.

 

    	54

    	 

    

 

14.4         Competition
Law.  

 

LICENSOR and TG agree
that nothing in this Agreement shall be interpreted in a way that conflicts with EC Block Exemption No: 418/85 on research and
development agreements, or EC Block Exemption No: 240/96 on technology transfer agreements, as issued by the European Commission
(as these may be amended or replaced from time to time).

 

14.5         Binding
Effect.

 

This Agreement shall
be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns.

 

14.6         Headings.

 

Section and subsection
headings are inserted for convenience of reference only and do not form a part of this Agreement.

 

14.7         Counterparts.

 

This Agreement may
be executed simultaneously in two or more counterparts, each of which shall be deemed an original and both of which, together,
shall constitute a single agreement.

 

14.8         Amendment;
Waiver.

 

This Agreement may
be amended, modified, superseded or canceled, and any of the terms of this Agreement may be waived, only by a written instrument
executed by each Party or, in the case of waiver, by the Party or Parties waiving compliance. The delay or failure of either Party
at any time or times to require performance of any provisions shall in no manner affect the rights at a later time to enforce the
same. No waiver by either Party of any condition or of the breach of any term contained in this Agreement, whether by conduct,
or otherwise, in any one or more instances, shall be deemed to be, or considered as, a further or continuing waiver of any such
condition or of the breach of such term or any other term of this Agreement.

 

14.9         No
Third Party Beneficiaries.

 

Except as set forth
in Sections 13.1 and 13.2, no Third Party (including, without limitation, employees of either Party) shall have or acquire any
rights by reason of this Agreement.

 

14.10      Section
365(n).

 

All licenses granted
under this Agreement are deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual
property” as defined in Section 101 of such Code. The Parties agree that TG may fully exercise all of its rights and elections
under the U.S. Bankruptcy Code and any foreign equivalent thereto in any country having jurisdiction over a Party or its assets.
The Parties further agree that, in the event TG elects to retain its rights as a licensee under such Code, TG shall be entitled
to complete access to any technology licensed to it hereunder and all embodiments of such technology. Such embodiments of the technology
shall be delivered to the TG not later than the commencement of bankruptcy proceedings against LICENSOR, upon written request,
unless LICENSOR elects to perform its obligations under the Agreement, or if not so delivered, upon the rejection of this Agreement
by or on behalf of LICENSOR, upon written request.

 

    	55

    	 

    

 

14.11         Purposes
and Scope.

 

The Parties hereto
understand and agree that this relationship is limited to the activities, rights and obligations as set forth in this Agreement.
Nothing in this Agreement shall be construed (a) to create or imply a general partnership between the Parties, (b) to make either
Party the agent of the other for any purpose, (c) to alter, amend, supersede or vitiate any other arrangements between the Parties
with respect to any subject matters not covered hereunder, (d) to give either Party the right to bind the other, (e) to create
any duties or obligations between the Parties except as expressly set forth herein, or (f) to grant any direct or implied licenses
or any other right other than as expressly set forth herein.

 

14.12         Assignment
and Successors.

 

Neither this Agreement nor any obligation
of a Party hereunder may be assigned by either Party without the consent of the other which shall not be unreasonably withheld,
except that each Party may assign this Agreement and the rights, obligations and interests of such Party, (a) in whole or in part,
to any of its Affiliates, or (b) in whole, but not in part, to any purchaser of all of its assets or all of its assets to which
this Agreement relates or shares representing a majority of its common stock voting rights or to any successor corporation resulting
from any merger, consolidation, share exchange or other similar transaction.

 

Notwithstanding the foregoing, by signing
the Agreement, TG is deemed to consent that LFB BIOTECHNOLOGIES, GTC and/ or LFB / GTC LLC may, at any time, assign their rights
and obligations under the Agreement to any of them or to any of their Affiliates.

 

14.13         Force
Majeure.

 

Neither TG nor LICENSOR
shall be liable for failure of or delay in performing obligations set forth in this Agreement, and neither shall be deemed in breach
of its obligations, if such failure or delay is due to a Force Majeure. In event of such Force Majeure, the Party affected shall
use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder.

 

14.14         Interpretation.

 

The Parties hereto
acknowledge and agree that: (a) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and
have contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting
Party shall not be employed in the interpretation of this Agreement; and (c) the terms and provisions of this Agreement shall be
construed fairly as to each Party and not in a favor of or against either Party, regardless of which Party was generally responsible
for the preparation of this Agreement. In addition, unless a context otherwise requires, wherever used, the singular shall include
the plural, the plural the singular, the use of any gender shall be applicable to all genders, the word “or” is used
in the inclusive sense (and/or) and the word “including” is used without limitation and means “including without
limitation”.

 

    	56

    	 

    

 

14.15         Integration;
Severability.

 

This Agreement, and
when executed, the Development Services and Manufacturing Agreement, the Commercial Supply Agreement(s) and the Stock Purchase
Agreement set forth the entire agreement with respect to the subject matter hereof and thereof and supersede all other agreements
and understandings between the Parties with respect to such subject matter. If any provision of this Agreement is or becomes invalid
or is ruled invalid by any court of competent jurisdiction or is deemed unenforceable, it is the intention of the Parties that
the remainder of this Agreement shall not be affected.

 

14.16         Further
Assurances.

 

Each of LICENSOR and
TG agrees to duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to
be done such further acts and things, including, without limitation, the filing of such additional assignments, agreements, documents
and instruments, as the other Party may at any time and from time to time reasonably request in connection with this Agreement
or to carry out more effectively the provisions and purposes of, or to better assure and confirm unto such other Party its rights
and remedies under, this Agreement.

 

[Remainder of page intentionally left
blank.]

 

    	57

    	 

    

 

IN WITNESS WHEREOF,
the Parties have caused this Agreement to be executed by their duly authorized representatives.

 

	 	GTC BIOTHERAPEUTICS, INC.
	 	 	 
	 	By:	/s/ William K. Heiden
	 	Name:	William K. Heiden
	 	Title:	CEO
	 	 	 
	 	LFB BIOTECHNOLOGIES S.A.S.
	 	 	 
	 	By:	/s/ Denis Soubeyran
	 	Name:	Denis Soubeyran
	 	Title:	 
	 	 	 
	 	LFB/GTC LLC
	 	 	 
	 	By:	/s/ Denis Soubeyran
	 	Name:	Denis Soubeyran
	 	Title:	
	 	 	 
	 	TG THERAPEUTICS, INC.
	 	 	 
	 	By:	/s/ Michael S. Weiss
	 	Name:	Michael S. Weiss
	 	Title:	CEO and President

 

 

    	58

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}]]